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Tian Tian
University of Nebraska Medical Center, 2018

Advisor: Kai Fu, M.D. Ph.D.
Aggressive B-cell lymphomas are diverse group of neoplasms that arise at different
stages of B-cell development and by various mechanisms of neoplastic transformation.
Aggressive B-cell lymphomas include many types, subtypes and variants of diffuse large
B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL) and B
lymphoblastic lymphoma. The treatment of patients with aggressive B-cell lymphomas
remains a clinical challenge. Conventional chemotherapeutic regimens, mainly based on
the CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) combination, obtain a relatively high number of complete or partial clinical responses (20-80%),
but the tumor relapses in most patients, who will die of the disease. Addition of rituximab,
a chimeric monoclonal antibody directed against CD20, to this combination increases
the overall survival, and the response rate and duration. However, different clinical evolution suggests that not all patients need the same therapy.
Rac1, a small guanosine triphosphatase (GTPase), has been found to be dysregulated
in many human malignancies, including solid tumors and chronic myeloid leukemia.
However, its status in MCL remains unknown. Here, we found Rac1 is overexpressed at
both mRNA and protein levels in MCL cell lines and cases, and over-expression is correlated with poor prognosis. Functional study showed that inhibiting Rac1 by shRNA or
specific inhibitor NSC 23766 significantly inhibited cell viability and enhanced chemotherapy drug Adriamycin-induced cytotoxic effect in MCL cells. Mechanistic studies
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showed diminished activity of several oncogenic pathways (AKT/mTOR, NF-κB and ERK)
upon Rac1 inhibition. However, as a GTPase, Rac1 is hard to target. Group I P21associated kinases (PAKs) are well known downstream of Rac1. Here, we demonstrated
overexpressed and highly activated Pak2 signaling in MCL, and in DLBCL and BL as
well. Inhibition of Pak2, not Pak1, by siRNA or inhibitor FRAX 597 significantly inhibited
lymphoma cells viability, through diminishing activity of AKT/mTOR and NF-κB pathways,
which furtherly confirmed the pro-survival role of Rac1-Pak2 axis in lymphoma situation.
Synergistic effect between FRAX 597 and Adriamycin or ibrutinib was shown in MCL.
Moreover, FRAX 597 could overcome the ibrutinib resistant in MCL and ABC-DLBCL.
Collectively, studies suggest targeting Rac1-Pak2 as a promising strategy in clinical
treatment of aggressive B-cell lymphomas.
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Chapter 1 Introduction
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B cells development, maturation and differentiation
B cells are generated from hematopoietic stem cells (HSCs) and develop in the
bone marrow before they migrate into the blood to reach peripheral lymphoid organs. Of
note, end-stage B cells (plasma cells), which develop following the activation of mature
B cells by antigen in peripheral lymphoid organs, are crucial for mediating humoral immune responses, return and colonize the bone marrow1.
The development of B cells happens in an ordered series of stages by the support of specific bone marrow environment. In developmental pathway from HSC to early
B-cell precursors, there are several precursor-cell subsets2. HSC, highly purified as lineage (Lin)-B220-KIT+SCA1+fms-related tyrosine kinase 3(FLT3)-CD34- cells, can give rise
to all blood-cell lineages3. Cells that are Lin-B220-KIT+SCA+FLT3+CD34+ have been
shown to lack erythroid-cell and megakaryocyte potential but retain myeloid-cell and
lymphoid-cell potential, these are termed lymphoid-primed multipotent progenitors
(LMPPs)4,5. LMPPs might represent a first step towards commitment to the lymphoid-cell
lineage. Arising from LMPPs is a cell population known as common lymphoid progenitors (CLPs), which are Lin-KITlowSCA1low interleukin-7 receptor (IL-7R)+ or LinAA4.1+SCA1lowIL-7R+ cells and can generate B- and T-lineage cells but not myeloidlineage cells6,7. The existence of these multipotent intermediates raises the possibility
that their differentiation into B cells is induced by the components of the specific niches7.
B-cell precursors, consisting of cells that are negative for cell-surface immunoglobulin
but positive for the B-cell-lineage marker B220, were divided into four subsets according
to their differential expression of a range of cell-surface markers during development in
the bone marrow7. These four subsets were termed fractions A, B, C and D. Because
fraction A cells have been shown to progress to fraction B or C phenotypes in in vitro
stromal-cell culture8, fraction A cells have been suggested to be the earliest identifiable
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B-cell precursors and subsequently been termed pre-pro-B cells. B cells undergo immunoglobulin-gene rearrangement during their differentiation; B-cell precursors first assemble a heavy-chain DJ rearrangement, which is then followed by heavy-chain variable
(V)DJ rearrangements9,10. Because most pre-pro-B cells lack heavy-chain DJ rearrangements, development of the early stages of B-cell precursors is likely to be independent of immunoglobulin-gene rearrangement. Fractions B and C consist mainly of
large mitotically active cells, which have heavy-chain DJ or VDJ rearrangements and are
termed pro-B cells11. Fraction D consists mainly of small resting cells, termed pre-B cells.
Immature B cells, which express cell-surface IgM but not IgD, are generated from the
cells in fraction D and then exit the bone marrow and reach the peripheral lymphoid organ, where they mature into peripheral mature B cells.
B cells that have successfully undergone V(D)J recombination that express functional B cell receptors (BCR) migrate as naïve B cells from bone marrow to the secondary lymphoid organs, including the spleen, lymph nodes, Peyer’s patches and tonsils12,13.
Here, germinal centers (GC) are developed. Naïve B cells first migrate to the T-cell zone
of lymphoid tissue, in where B cells become fully activated by their interaction with CD4+
T cells and antigen presenting cells (APC). The most important and well-studied costimulatory receptor-ligand interaction is that between the tumor necrosis factor (TNF)receptor family member CD40, which is expressed by all B cells, and its ligand CD154
expressed by CD4+ T cells14. Activated B cells can then either develop directly into antibody-secreting cells in specialized extrafollicular sites, such as the medullary cords of
lymph nodes, or mature into GC-precursor B cells and move to the primary follicle, which
is made of recirculating IgM+IgD+ B cells within a network of follicular dendritic cells
(FDCs)15. Here, B cells start to proliferate rapidly and push the IgM+IgD+ B cells aside to
form the mantle zone around the GC, which yielded the secondary follicle. The charac-
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teristic structure of the GC, a dark zone and a light zone, becomes apparent after a few
days of vigorous proliferation. Histologically, dark zone consists of almost exclusively of
densely proliferating B cells known as centroblasts, whereas in the light zone, the B cells,
known as centrocytes, are intermingled with FDCs, T cells and macrophages. Functionally, the dark zone is the site of B cell division and somatic hypermutation (SHM),
whereas the light zone is where B cells undergo activation and selection based on the
affinity of their BCR. Cycling of centroblasts and centrocytes between dark and light
zones seems to be mediated by signals from the BCR and other GC resident cells16-18.
These signals involve signal transduction molecules and nuclear transcriptional effectors
that are often structurally and functionally altered during lymphomagenesis17. Antigenselected centrocytes eventually differentiated into memory B cells or plasma cells.
Inducing GC B cells to differentiate into plasma cells or memory cells requires
various signals. The first event is the functional inactivation of the transcriptional repressor paired box 5 (PAX5), which is essential for maintain the identity of mature B cell,
including naïve, GC and memory B cells. A second event that is required for post-GC
differentiation is the downregulation of B-cell lymphoma 6 (BCL6), which is thought to
terminate the GC transcriptional programme and allow for GC B cells to differentiate into
memory B cells or plasma cells. Moreover, the expression of B lymphocyte-induced
maturation protein 1 (BLIMP1), interferon-regulatory factor 4 (IRF4) and X-box-binding
protein 1 (XBP1) are all jointly required for this differentiation process19. All those pathways must be orderly regulated to maintain the normal immune response.
BCR structure and signaling
For effective humoral immunity, mature B cells must respond to foreign antigens
and generate antigen-specific effector cells. This later stages of B cell maturation requires the BCR complex. The BCR is required also during early B-cell ontogeny for
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maintenance. In other words, the BCR has two main roles. The first is to transmit signals
that regulate B-cell fate decisions. The second is to mediate antigen processing, leading
to the presentation of antigen to T cells, which allows full activation of B cells in the effector phase. These two roles are interrelated, but are under distinct genetic control.
The BCR complex is made up of immunoglobulin heavy (IgH) and light (IgL)
chains associated with two signaling components, Igα and Igβ. After BCR ligation by antigen, both the protein tyrosine kinase (PTK), spleen tyrosine kinase (SYK), and Srcfamily PTKs such as LYN, are activated initially20. Then LYN phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic tails of Igα and Igβ,
which, in turn, recruit and facilitate the activation of SYK and the TEC-family PTK, bruton
tyrosine kinase (BTK). Phosphatidylinositol 3-kinase (PI3K) and phospholipase Cγ2
(PLCγ2) are important downstream effectors of BCR signaling. B cell adaptors, such as
B-cell linker (BLNK) and BAM32 (B lymphocyte adaptor molecule of 32kDa), fine-tune
BCR signals by efficiently connecting the above kinases with the effectors. PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PtdInsP2) to produce phosphatidylinositol-3,4,5-triphosphate (PtdInsP30), which, in turn, recruits some BCR signaling components and also activates downstream kinase such as protein kinase B (AKT). Activation of PLCγ2 induce the release of intracellular calcium and activation of protein kinase
C (PKC), both of which are crucial for the activation of mitogen-activated protein kinase
(MAPK)-family kinases, such as extracellular signal-regulated kinase (ERK), c-JUN
NH2-terminal kinase (JNK) and p38 MAPK, and transcription factors, including nuclear
factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT)21,22.
The BCR induced signaling pathways are crucial for the survival and proliferation
of B cells. These include the PI3K, RAS-RAF-ERK and NF-κB pathway. Firstly, PI3KAKT pathway is a primary candidate for mediating B-cell survival in the base of treat-
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ment of B cells with inhibitors of PI3K leading to an increase in BCR-induced cell death.
AKT functions to protect against BCR-induced cell death and to promote B-cell survival
in the resting state. The specific mechanism is by inhibiting activation of the proapoptotic B-cell lymphoma 2 (BCL2)-family member BAD (BCL2 antagonist of cell death)
and inhibiting glycogen synthase kinase 3 (GSK3) kinase in B cells. Secondly, the activation of ERK is regulated in a PLCγ2-dependent manner, also in a PLCγ2-independent
manner, most probably through the RAS-RAF pathway. Although it is clear that ERK is
involved in the survival of other cell types, its role in immature B cells is unclear and
needed to be clarified. Thirdly, NF-κB can protect many cells from pro-apoptotic signals.
Activation of PLCγ2 is absolutely required for BCR-induced NF-κB activation in B cells.
Activation NF-κB, on the one hand, could induce the expression of anti-apoptotic BCL2family members, such as BCL2, BCL-XL (B-cell lymphoma-extra large) and A1, on the
other hand, could increase the cyclin D2 expression. Normally, BCR expression at the
cell surface might generate a basal “tonic” signal, which include the activation of NF-κB,
which is sufficient for cell survival. This is the case for immature B cells. However, in mature B cells, basal NF-κB signaling acts as a maintenance signal for cell survival. Moreover, BCR ligation probably induces additional survival signals, such as AKT, ERK and
NF-κB to override death signals22.
BCR complex plays an important role in directing generating mature B cells subsets. Productive variable-region and joining-region rearrangements of the immunoglobulin light chain (VLJL rearrangements) are completed in pre-B cells, and expression of the
BCR drives pre-B cells to the immature B-cell stage. This process could generate potentially harmful, self-reactive B cells. An important role of BCR at this stage is to induce
efficient elimination of these potentially harmful cells. Immature B cells that have passes
successfully through developmental checkpoints in the bone marrow emigrate subse-
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quently to the spleen as transitional B cells, which then become mature B cells. Transitional B cells can be divided further into two subsets, type 1 (T1) and T223. T1 cells are
recent emigrants from the bone marrow, which means that their phenotype is related
closely to that of immature B cells in the bone marrow. T1 cells express no or low levels
of immunoglobulin D (IgD), CD21 and CD23, but high levels of surface immunoglobulin
M (sIgM). Only a small percentage of T1 cells can successfully enter B-cell follicles become T2 cells. T2 cells have a mixed phenotype between that of T1 B cells and mature
follicular B cells. They still express high levels of sIgM, but also express high levels of
surface (s)IgD, CD21, and CD23. BCR signaling pathways are different in T1 and T2
cells. After BCR crosslinking, T2 cells express much higher level of cyclin D2 or A1 and
active AKT compared with T1 cells. Studied have shown that BCR signaling is required
for the T1 to T2 transition. BCR signals facilitate T2-cell generation and maintain T2-cell
survival perhaps by enhancing the activation of NF-κB. Final step, transition from the T2
to mature B cells, also requires BCR signals23. Mature B cells are classified into at least
three subsets, follicular B cells, marginal-zone (MZ) B cells and peritoneal B cells24.
Studied have indicates that BCR signaling induced by self-ligands is required for the
generation and maintenance of all three mature subsets. Moreover, some ongoing BCR
signals from foreign ligands or antigens are required for B cells to survive.
Aggressive B-cell lymphomas and its classification
Aggressive B-cell lymphomas are diverse group of neoplasms that arise at different stages of B-cell development and by various mechanisms of neoplastic transformation. The aggressive B-cell lymphomas include many types, subtypes and variants of
diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), mantle cell lymphoma
(MCL) and its blastoid variant, and B lymphoblastic lymphoma25.
Mantle cell lymphoma
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MCL classically has been recognized as an aggressive but incurable small B-cell
lymphoma. MCL is developed in a linear fashion from naïve B cells. MCL has two subtypes, which are recognized with different clinic-pathological manifestations and molecular pathogenic pathways. Classical MCL is composed of IgH Variable-region (IGHV)unmutated or minimally mutated B cells that express SOX11 (sex determining region Ybox 11) and typically involves lymph nodes and other extranodal sites. Acquisition of additional molecular abnormalities can lead to even more aggressive blastoid or pleomorphic MCL. Other MCL develop from IGHV-mutated SOX11- B cells which leads to
leukemic nonnodal MCL with the peripheral blood, bone marrow and spleen involvement.
These cases are frequently clinically indolent, however, will become aggressive after
secondary abnormalities. In situ MCL is now to be called in situ mantle cell neoplasia
(ISMCN), emphasizing the low rate of progression. It is characterized by the presence of
cyclin D1+ cells26,27.
Diffuse large B-cell lymphoma, NOS
Based on gene expression profiling (GEP), DLBCL can be divided into two subgroups, germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL. This is
cell-of-origin classification28. A significant advance in recent years has been the better
understanding of MYC alterations in large B cell lymphomas. MYC is rearranged in 5%
to 15% of DLBCL NOS, is frequently associated with BCL2 or, to a lesser extent, BCL6
translocation, in the so-called “double-hit” or “triple-hit” lymphomas. This type of lymphoma is included in the updated WHO classification in the new category of high-grade
B-cell lymphoma (HGBL), with rearrangements of MYC and BCL2 and/or BCL6. MYC
protein expression is detected in a much higher proportion of DLBCL (30%-50%) and is
associated with concomitant expression of BCL2 in 20% to 35% of cases. Most of these
tumors do not carry MYC/BCL2 chromosomal alterations and have been named “double-
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expressor lymphoma.” Cutoff to define these cases for MYC expression is 40%, for
BCL2 expression is 50%. According to 2016 WHO27, double expression of MYC and
BCL2 proteins without gene aberrations should be considered a prognostic indicator in
DLBCL, NOS but not a separate category.
Burkitt lymphoma
BL cells are derived from the GC B cells. These tumors carry specific chromosome translocations, that is, t(8;14)(q24;q32) or its variants. Mutations in the transcription factor 3 (TCF3) or its negative regulator ID3 (inhibitor of DNA Binding 3) occur in
about 70% of sporadic and immunodeficiency-related BL and 40% of endemic cases.
The subset of lymphomas that resemble BL morphologically, to a large extent phenotypically and by GEP, but lack MYC rearrangements, has been included in a new entity in
the 2016 WHO classification called Burkitt-like lymphoma with 11q aberration27.
Cellular origin and genetic alterations in aggressive B-cell lymphomas
Mantle cell lymphoma
MCL represents 5%-10% of all non-Hodgkin’s lymphomas (NHL), and predominantly occurs in males with advanced age. The neoplastic cells in MCL are mature Blymphocyte that expressed genes normally detected in naïve B cells, such as IgD and
the T-cell-associated CD5 antigen, and tend to colonize the mantle zone of the lymphoid
follicles. These propose the term MCL and suggest that the cell origin of MCL is naïve B
cells.
MCL is genetically characterized by the t(11;14)(q13;q32) translocation that juxtaposes the proto-oncogene CCND1, which encodes cyclin D1, at chromosome 11q13,
to the Ig heavy chain gene at chromosome 14q32. As a consequence of the translocation, cyclin D1, which is not expressed in normal B lymphocytes, becomes constitutively
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overexpressed29. This genetic alternation is thought to be the primary event in the pathogenesis of the tumor, probably facilitating the dysregulation of the cell cycle at the G1-S
phase transition. Cyclin D1 participates in the control of the G1 phase by binding to cyclin-dependent kinase (CDK) 4 and CDK6. Cyclin D1-CDK4 and cyclin D1-CDK6 complexes could phosphorylate retinoblastoma 1 (RB1) and lead to the inactivation of its
suppressor effector on cell cycle progression30. The overexpression of MCL cells also
titre p27 into CDK4-cyclin D1 complexes rendering p27 incapable of inducing G1 cell
cycle arrest. There is a small subset of tumors negative for cyclin D1 and t(11;14) but
with a morphology, phenotype, global-expression profile and secondary genetic events
undistinguishable from conventional MCL, suggesting that they correspond to the same
disease. However, these cases have high expression of cyclin D2 or cyclin D331. These
cases are uncommon but highlight the relevance of the oncogenic dysregulation of the
G1 phase of the cell cycle in the pathogenesis of MCL. Despite the important role of the
t(11;14) translocation and cyclin D1 overexpression in the development of MCL, several
observations suggest that these mechanisms may not be sufficient for the full transformation of the cells and the aggressive behavior of the tumor. Cytogenetic studies aimed
at identifying secondary genetic alternations have revealed that MCL is one of the malignant lymphoid neoplasms with the highest level of genomic instability. The recurrent
aberrations of certain chromosomal regions have been identified, such as losses of 11q
and 13q, gains of 3q and 12q and losses of 9p, 9q and 17p. Alterations of the 8q24 locus,
including the t(8;14)(q24;q32) translocation that activates MYC, are uncommon but have
been identified in MCL with a very rapid clinical evolution. Besides these chromosomal
imbalances, MCLs present frequent tetraploid clones that are more common in pleomorphic and blastoid variants than in cases with typical morphology.
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The potential targets genes in the chromosomal regions altered in MCL are mainly belonging to two pathogenic pathways: the cell cycle and the DNA damage response.
In cell cycle dysregulation, highly proliferative MCL carry two main oncogenic pathways
alteration, INK4a-CDK4-RB1 and ARF-MDM2-p53, which are responsible for the control
of the cell cycle and senescence. Tumor obtains a selective advantage inactivating
those pathways. For DNA damage response pathways alteration, deletion of the ataxiatelangiectasia mutated (ATM) gene is the most frequent event. The inactivation of ATM
facilitates the development of genomic instability and increases tumorigenesis in these B
cells. In addition, MCL may also have activated cell survival mechanisms. Specifically,
amplification of anti-apoptotic BCL2 and homozygous deletions of BIM, a gene of the
pro-apoptotic BH3-only family, have been observed in several MCL cell lines. Constitutive activation of NF-κB has been detected in MCL cell lines and primary tumor with
overexpression of downstream targets such as FADD-like apoptosis regulator (FLIP).
The AKT survival pathway is also activated in MCL, which might be associated with loss
of phosphatase and tensin homologue (PTEN) expression. Currently, new drugs targeting these mechanisms are increasingly available26,32.
Burkitt lymphoma
BL includes sporadic, endemic and HIV associated forms. It is an aggressive malignancy derived from GC dark zone B cells, as indicated by the presence of mutated IgV
sequences and its transcriptional signature. All endemic and 1/3 of all sporadic and
AIDS-associated BL cases are infected by the Epstein-Barr virus (EBV). Genetic alternations in BL lead to the aberrant expression of MYC and to the activation of the PI3K signaling pathway, both of which are not part of the physiological programme of the dark
zone B cells.
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Translocations of the MYC oncogene into the immunoglobulin loci are present in
100% of cases and therefore are the hallmark of BL. The translocation leads to the ectopic and constitutive expression of MYC as a result of the escape from the BCL6mediated transcriptional repression that normally prevents MYC expression in dark zone
B cells. MYC is a nuclear phosphoprotein that functions as a sequence-specific DNAbinding transcriptional regulator to control proliferation, cell growth, differentiation and
apoptosis, all of which are implicated in carcinogenesis. MYC promotes genomic instability by inducing replication stress, which is particularly dangerous when activated in
highly proliferative dark zone B cells. Approximately 70% of BL have either mutation of
TCF3, which encodes the transcription factor E2A, or inactivating mutations in ID3,
which prevent its regulation of E2A. The resulting dysregulated activity of E2A seems to
promote antigen-independent “tonic” BCR signaling. The PI3K pathway happens to be a
key component of tonic BCR signaling. Whereas other pathways, including NF-κB or
MAPK, which are essential effectors of the antigen-dependent BCR pathway, are shown
to be dispensable. Besides, 1/3 of individuals with BL have inactivating mutations of
several tumor suppressors including tumor protein 53 (TP53), PTEN and cyclindependent kinase inhibitor 2A (CDKN2A)17,18.
Diffuse large B cell lymphoma
DLBCL is the most common form of B-NHL and account for ~40% of all new diagnoses of B-NHL in adulthood. It includes cases that arise de novo as well as cases
that derive from the clinical evolution of various less aggressive B-NHLs, such as follicular lymphoma and chronic lymphocytic leukemia. Based on gene expression profiles,
DLBCLs correspond to B cells arrested by transformation events that occur at various
stages of the GC transit. In particular, GCB-like subtype DLBCL resemble light zone B
cells, whereas ABC-like DLBCLs seem to derive from GC cells arrested during the early
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stages of post-GC plasma cell differentiation (plasmablasts). These molecular phenotypes have prognostic value; ABC-DLBCL has a more aggressive clinical course and
more unfavorable outcome than GCB-DLBCL. Consistent with their distinct molecular
phenotype and clinical course, each DLBCL subtype shows predominant or exclusive
genetic aberrations, although they still share some pathogenetic alternations, including
those involving chromatin modifiers, BCL6 dysregulation and immune recognition.
The pathogenesis of the GCB subtype of DLBCL is poorly understood. A few biologically relevant lesions have been identified, but each of them is present only in a fraction of cases. Chromosomal translocations involving MYC and BCL2, which are analogous to those that characterize BL and follicular lymphoma, are detected in ~10% and
~40% of GCB-DLBCL, respectively. The co-occurrence of lesions affecting the MYC and
BCL2 genes is associated with a particularly poor prognosis. In addition, two programmes seem to be affected with some specificity in GCB-DLBCL: EZH2 (enhancer of
zeste homolog 2)-driven epigenetic changes and B cell migration. EZH2 gene is mutated
in ~21% of GCB-DLBCL cases and its mutations result in a gain-of-function phenotype.
Mice studies engineered to express the mutation develop GC hyperplasia, which indicates that mutations in EZH2 contribute to lymphomagenesis. Moreover, mutations of
several chemokines and receptors in GC have been shown in 30% GCB-DLBCL, including sphingosine-1-phosphate receptor 2 (S1PR2) and P2Y purinoceptor 8 (P2RY8),
GNA13 (which encodes Gα13) and ARHGEF1 (which encodes RHO guanine nucleotide
exchange factor 1). All those mutations contribute to the loss of confinement of B cells to
the GC. In addition, they provide an explanation for the ability of GCB-DLBCL cells leave
their tissue of origin and travel to distant sites, such as bone marrow.
The pathogenesis of ABC-DLBCL is characterized by two main events: the constitutive activation of NF-κB and the blockade of terminal different ion to plasma cells.
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Both events can be achieved by distinct genetic lesions. Constitutive NF-κB signaling is
sustained by a variety of genetic alterations. In ~20% of ABC-DLBCL cases, mutations in
CD79A and/or CD79B (which encodes components of the BCR complex) contribute to
chronic BCR signaling by preventing endocytosis of the receptor and/or by blunting the
activity of LYN, which is a negative regulator of the pathway. Activating mutations targeting CARD11 (recruiting domain-containing protein 11) in ~10% ABC-DLBCL lead to
hype-responsiveness of the signal transduction complex CARD11-BCL10-MALT1 to activate NF-κB independently of upstream signals, including BCR. ~35% ABC-DLBCL cases carry MYD88 (myeloid differentiation primary response protein 88) mutation. On the
one hand, MYD88 mutation leaded to gain the ability of spontaneously assembling a
complex containing interleukin 1 receptor-associated kinase (IRAK1) and IRAK4, which
leads to activation of NF-κB. On the other hand, MYD88 mutations induce Janus kinase
(JAK)-signal transducer and activator of transcription 3 (STAT3) signaling. Besides these
mutations, the inactivation of TNFAIP3 (TNF alpha induced protein 3) gene, which encodes a key negative modulator of NF-κB pathway, has been found in 30% of ABCDLBCL cases, thus preventing termination of NF-κB responses. All those alterations described above could not exclude the possibility that constitutive activation of NF-κB may
occur as a consequence of chronic stimulation of the BCR by antigens or autoantigens.
The inability of ABC-DLBCL cells to terminally differentiate seems to depend on two
mechanisms that are mostly mutually exclusive and that converge on the negative regulation of the plasma cell master regulator BLIMP1. Bi-allelic inactivation of PRDM1 (PR
domain zinc finger protein 1) is observed in ~30% of ABC-DLBCL cases. Alternatively,
BCL-6 dysregulation by chromosomal translocations, which are more frequently in ABCDLBCL than GCB-DLBCL, also leads to constitutive repression of PRDM1 by BCL6.
Studies have shown that mice with GC B cells that carry inactivated PRDM1 develop
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ABC-DLBCL that shows constitutive NF-κB activation, which indicates that both of these
pathways are required for this type of lymphomagenesis17,18.
Current therapies and challenges for aggressive B-cell lymphomas management
The treatment of patients with aggressive B-cell lymphomas remains a clinical
challenge. Conventional chemotherapeutic regimens, mainly based on the CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) combination, obtain a
relatively high number of complete or partial clinical responses (20-80%), but the tumor
relapses in most patients, who will die of the disease. Addition of rituximab, a chimeric
monoclonal antibody directed against CD20, to this combination increases the overall
survival, and the response rate and duration. Other intensive chemotherapy regimens
such as hyper-CVAD and combination with rituximab or stem cell transplantation have
also been used for initial treatment.
In the past few years, new strategies have been developed that target crucial biological cellular pathways and that may change the management and outcome of patients.
Proteasome inhibitors
Proteasome targets such as cyclin D1, TP53 and NF-κB are altered in multiple
types of B cell lymphomas, justifying the emergence of the proteasome as an attractive
target for aggressive B-cell lymphomas treatment. Clinical evidence demonstrated that
bortezomib (first-in-class proteasome inhibitor) treatment induces a high percentage of
responses and superior overall survival in MCL and ABC-DLBCL compared with GCBDLBCL.
BCR signaling inhibitor
BTK has been shown to be an essential component of chronic active BCR signaling, which is a key survival pathway in the ABC-DLBCL. Potent BTK pharmacologic in-
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hibitor (ibrutinib) kills ABC cells, which had been identified in many studies33. In addition,
a moderate to strong BTK expression has been found in MCL. Ibrutinib inhibited the viability of MCL cell line in concentration- and time-dependent manners, also induced a
concentration-dependent apoptosis. Studies also demonstrated that ibrutinib treatment
resulted in significant improvement in progression-free survival (PFS) and good tolerability in patients with relapsed or refractory MCL. Currently, the challenge for ibrutinib is
that both primary and secondary resistance has been reported in various lymphomas.
Resistance may arise due to mutations that impair the affinity of ibrutinib for BTK, or due
to alterations in pathways downstream of BTK and may confer BCR signaling independence in resistant clones.
Apoptosis inhibitor
Apoptosis execution depends on the activation of caspases by either the intrinsic
(mitochondrial) pathway or the extrinsic pathway that requires activation of the TNF family of cell death receptors (FAS, DR4 and DR5) by their related ligands (FAS ligand) and
TNF-related apoptosis inducing ligand (TRAIL). BCL2 family proteins are the most prominent regulators of the intrinsic apoptotic pathway. Preclinical data from lymphoma cell
lines and primary tumor samples indicate high efficacy of BCL2 inhibitor against lymphoma. In parallel, the extrinsic pathway has emerged as a potential target in therapeutics, particularly because chemo-refractory cells often have defects in their intrinsic
pathway. Agents such as TRAIL or anti-DR4 and 5 humanized antibodies that selectively
kill tumor cells have recently been shown to be effective in lymphoid tumors34.
Inhibition of survival pathways
PI3K-AKT-mTOR (mammalian target of rapamycin) acts as a central controller of
multiple growth signaling pathways. mTOR inhibitors have arisen as promising agents
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for cancer therapy, such as Temsirolimus, which has shown anti-tumor activity in lymphoma35.
Aggressive B-cell lymphomas follow a very rapid progression. At present, the
therapeutic approaches are relatively similar in all patients, and the different strategies
do not consider this potential variation. However, different clinical evolution suggests that
not all patients need the same therapy. Developing precise and reliable criteria to predict
such disparate clinical behavior and adjusting the best therapeutic strategy for each individual patient are needed. Promisingly the increasing number of drugs that target specific molecular mechanisms is opening new perspective for lymphoma patients, but the
evaluation of these approaches will require a correct stratification of the patients according to the specific biological risk of their disease. Moreover, deciphering the pathogenesis of B-cell lymphoma is needed to identify novel treatable targets for better therapeutic
intervention32,36.
Rho-family GTPases (guanosine triphosphatase) and their roles in cancer
Rho-family GTPases have been recognized as crucial signal-transducing proteins for almost 20 years. It comprised a family of 23 proteins that are related in primary
sequence. Phylogenetic analysis shows that these proteins cluster into several subfamilies based on sequence similarity. The prototypical members of the family, Rac1 (Rasrelated C3 botulinum toxin substrate 1), CDC42 (Cell division control protein 42) and
RHOA (Ras homolog gene family, member A), can bind both GTP and GDP. When
bound to GTP they are active and can transduce signals by binding to effector proteins.
By contrast, the GDP-bound forms do not bind effector proteins and are generally assumed to be inactive. However the Rnd (Rho-related GTP-binding protein family),
RhoBTB (Rho-related BTB domain-containing protein family), RHOH, RHOU and RHOV
GTPases are atypical and do not conform to this stereotypical mechanism of regulation
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as they are mainly GTP bound. They might instead be regulated by expression, phosphorylation or stability37,38.
The switch between the GDP- and GTP- bound forms of typical Rho GTPase is
regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). When in the GTP-bound active form, Rho family GTPase transduced signals by binding to effector proteins. These in turn are involved in many cellular processes including regulation of the actin cytoskeleton, microtubule dynamics, cell division, migration and adhesion. There are 79 identified GEFs for Rho family GTPases in the
mammalian genome. 65 Rho family GAPs are known in mice.
A branch of Rho GTPases are involved in tumorigenesis. There is increasing evidence that Rho proteins are dysregulated during tumor progression and that this correlated with poor prognosis. On the one side, Rho proteins can promote cell-cycle progression, which is controlled by CDKs. Rho proteins affect CDK activity by regulating the
levels of cyclin D1, as well as P21WAF1 and P27KIP1, which bind to and modulate CDK activity39. On the other side, evidence showed that RHO proteins might protect cells
against apoptosis. Additionally, modulation of Rho protein activity can promote the metastasis of tumor cells by disrupting epithelial-sheet organization, increasing cell motility
and promoting the degradation of the extracellular matrix. Given the involvement of Rho
proteins in cancer, they might make good therapeutic targets.
Overview of the chapters
The overall goal is to study the role of Rac1-PAK (p21-activated kinases) axis in
aggressive B-cell lymphomas, particularly MCL, and identify potential candidates in effective therapy or combination therapy.
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In Chapter 2, Rac1 has been identified as commonly activated in MCL. In addition, we have demonstrated Rac1 play a tumorigenesis role in MCL by activating multiple oncogenic pathways, such as AKT/mTOR and NF-κB pathway, and inhibition of
Rac1 enhanced the cytotoxic effect induced by Adriamycin. The evidence supported a
concept of targeting Rac1 might be a potential strategy for treating MCL. However, one
problem is that Rac1 is GTPase, which is hard to target. Considering the function of
Rac1 is through activation of PAKs, known as Rac1-PAK axis, and PAK is a kinase,
which makes targeting PAK a better choice. In Chapter 3, we have identified that inhibiting Rac1-Pak2 axis, not Pak1, significantly inhibit the tumor cells growth in MCL, also in
other aggressive B-cell lymphoma cells. Additionally, synergistic effect was observed
between PAK inhibitor and Adriamycin or Ibrutinib in MCL. Moreover, PAKs inhibitor
could overcome ibrutinib resistant in treating ibrutinib-resistant MCL and ABC-DLBCL
cell lines. In Chapter 4, the major conclusion was summarized and future directions were
discussed. Chapter 5 and Chapter 6 are materials and methods section and bibliography
section, respectively.

20

Chapter 2 Rac1 is a novel therapeutic target in mantle cell lymphoma

Parts of this chapter are derived from:
Tian T*, Bi CF, Hein AL, Zhang X, Wang C, Shen SF, Yuan J, Greiner TC, Enke C,
Vose J, Yan Y, Fu K. Rac1 is a novel therapeutic target in mantle cell lymphoma.
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Summary
Rac1 is a small guanosine triphosphatase (GTPase), which plays a critical role in cell
survival, migration and transformation. Rac1 has been found to be dysregulated in many
human malignancies, including solid tumors, chronic myeloid leukemia, and peripheral T
cell lymphomas. However, its status in MCL remains unknown. Here, we investigated
the expression of Rac1 in MCL and found it is overexpressed at both mRNA and protein
levels. Furthermore, the level of Rac1 protein in MCL primary tumors is correlated with
poor prognosis of MCL patients. To determine the significance of Rac1 dysregulation in
MCL, we knocked down Rac1 in MCL cell lines using shRNA. The result shows that decreasing Rac1 level in MCL cells significantly inhibited the proliferation and enhanced
chemotherapy drug Adriamycin (doxorubicin)-induced cytotoxic effect. Consistently, inhibition of Rac1 using a specific inhibitor NSC 23766 in MCL cells showed a similar effect as Rac1 knockdown by shRNA. Mechanistic studies demonstrated that inhibition of
Rac1, either by shRNA or by chemical inhibitor, substantially diminished the activity of
signaling pathways downstream of Rac1, including pathways of AKT/mTOR, NF-κB and
ERK. Collectively, the studies of the report suggest targeting Rac1 as a promising strategy in clinical treatment of MCL.
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INTRODUCTION
MCL is an aggressive hematological malignancy, comprising 6-8% of human Bcell lymphomas40. Cytogenetically, MCL is characterized by the chromosomal translocation t(11;14)(q13;q32), which results in aberrant expression of cyclin D141. Rituximab
(R)-CHOP, which combines rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin
and prednisone, is the most common chemotherapeutic treatment approach used to
treat MCL. Despite the improvement of the overall survival with intensive frontline chemotherapy, it remains an incurable disease and most patients are destined to relapse after
initial therapy42. The median survival of patients with MCL ranges between 3 and 5
years43. Therefore, new strategies are urgently needed for the treatment of MCL. Increasingly, seeking for the drivers of MCL pathogenesis will elucidate potential targets
for therapeutic intervention of this disease.
Rac1, a member of the Rho family, is small GTPase. Studies have shown that
Rac1 plays a critical role in cell proliferation, migration and survival44. Rac1 bears two
conformational states, inactive GDP-bound form and active GTP-bound form. The transition of Rac1 between these two forms is regulated by its GEFs and GAPs. GEFs promote Rac1 activation by driving the switch of GDP to GTP-bound activated form. Oppositely, GAPs inactivate Rac1 through GTP hydrolysis, by which Rac1 switches to GDPbound inactivated form45. In the active state, Rac1 interacts with multiple effectors and
activates numerous downstream signaling pathways, such as PI3K/AKT, AMPK and
PAK/ERK pathways46-48.
Overexpression of Rac1 has been reported in several types of solid tumors, including breast cancer and pancreatic cancer49-52. In these tumors, activation of AKT, NFκB and c-RAF/MEK/ERK pathways play a major role in Rac1 promoted oncogenesis,
survival and metastasis47,48,52-55. In hematological malignancies, studies have shown that

23
Rac1 GTPase activated by BCR-ABL represented a novel target in Chronic Myeloid
Leukemia (CML). Treatment with the specific Rac1 inhibitor NSC 23766 remarkably
suppressed the growth of primary bone marrow cells from patients with blast phase CML
as well as leukemia cells ectopically expressing BCR-ABL T315I56.
Interestingly, AKT signaling is one of the most commonly dysregulated oncogenic
pathways in MCL. Constitutively activation of PI3K/AKT/mTOR pathway has been shown
to contribute to survival in a subset of MCL57-59. These signaling results in the activation
of a number of well-known target genes and pathways, including the NF-κB pathway, a
second major oncogenic signaling pathway postulated to be activated independently in
MCL59. Studies also showed that ERK1/2 pathway is critical to the proliferation and survival of MCL through inhibiting BCL family BCL-xl60. Cross talk between these pathways
has been reported previously in a number of studies59.
Despite the widely study of Rac1 in solid tumor and myeloid malignancies, its
role in MCL remains unclear. In the current study, we have assessed the expression of
Rac1 in MCL cell lines and tissues, and its correlation with clinical outcome. We also investigated the effects of Rac1 on its downstream oncogenic signaling pathways, as well
as the impact of Rac1 on cell proliferation, survival and anticancer drug response in MCL
cells. Adriamycin, the core agent of R-CHOP regimen, was used as standard treatment
in the drug combination part.
RESULTS
Rac1 is overexpressed in MCL patient samples and cell lines
GEP was done on total 41 MCL cases from LLMPP (Lymphoma/leukemia Molecular profiling project) database, and expression of all members of Rho GTPases family was shown in figure 2.1A. Next, we compared the expression levels of those GTPases
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in MCL and in naïve B cells. We found that three genes, which are RHOU, RHOBTB3
and Rac1, displayed substantial higher expression in MCL cases than in naïve B cells
(p<0.05) (Figure 2.1A). Heat-map was also shown here to emphasize the relative expression difference (Figure 2.1B). Of these three genes, Rac1 has an overall higher expression mRNA level in MCL cases than the other two. Combined with the relative higher expression of Rac1 in MCL than naïve B cells (Figure 2.1C), which make Rac1 be a
potential research candidate in the following study. Moreover, this result was further confirmed by analyzing 64 MCL cases from online database (Figure 2.2). We also examined
the levels of Rac1 mRNA and protein in a panel of 6 MCL cell lines (Granta-519, Jeko-1,
JVM2, Maver-1, Mino and Z138). The result showed that, while Rac1 mRNA is expressed at higher levels in 4 of the MCL cell lines (Jeko-1, Maver-1, Mino and Z138)
than Naïve B cells (Figure 2.3A), the protein level is markedly increased in all of the
tested MCL cell lines compared to the normal control Naïve B cells (Figure 2.3B). Moreover, the Rac1-GTP level also increased in MCL cell lines compared to the normal control, which means that Rac1 is activated in all MCL cell lines (Figure 2.3B). It is worth
noting that the mRNA expression of Rac1 is not well correlated with its protein level, implying that post-transcriptional or translational regulation plays a part in Rac1 expression
in MCL cells.
To confirm the up-regulation of Rac1, we performed immunohistochemistry (IHC)
analysis of Rac1 in 32 cases of MCL. In normal lymphoid follicles, mantle zones were
negative for Rac1 (Representative Figure 2.4A-B), whereas 18 cases of MCL (56%)
showed positive reactivity to Rac1, with six respective cases fell into weak, medium and
strong staining (cut-off value 30%) (Table 2.1 and Figure 2.4C-D). Furthermore, we analyzed the prognosis of these MCL cases, and found that Rac1 positive staining was associated with shorter overall survival (OS, p=0.039) in MCL patients (Figure 2.5). These
data suggest that dysregulation of Rac1 signaling is involved in MCL progression.
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Knockdown of Rac1 inhibits the proliferation and increase the cytotoxic effect of
Adriamycin
To confirm the significance of Rac1 dysregulation in MCL, the 41 cases were
then divided into three groups based on Rac1 mRNA level and correlated with cell proliferation. As shown in supplemental Figure 2.6, higher Rac1 level was significantly correlated with higher levels of the proliferation signature, as established in our previous study
(p<0.001). Next, we transduced MCL cell lines Z138 and Mino, which express high levels of both Rac1 and Rac1-GTP (Figure 2.3B), with Rac1-shRNA by inducible retroviral
vector. Upon doxycycline (Dox) induction, Rac1 protein level was decreased by 55% and
50% in Z138 and Mino cells, respectively, compared to the vector controls (Figure 2.7AB). Notably, knockdown of Rac1 decreased cell proliferation by 43% (p<0.001) and 24%
(p=0.002) in Z138 and Mino cells, respectively, after three days of continuous culture
(Figure 2.8A-B). However, Rac1 knockdown did not induce any cell apoptosis in those
two MCL cell lines (Figure 2.9A-B).
We also examined the effect of Rac1 on chemotherapy drug Adriamycin-induced
cytotoxic effect in MCL cells. As shown in Figure 2.9A-B, even if Rac1 knockdown itself
has little effect on the apoptosis in Z138 and Mino cells, when combined with Adriamycin,
Rac1 knockdown cells exhibited an enhanced Adriamycin-induced apoptosis, with a
nearly 2-fold increase in apoptosis observed in the Rac1 knockdown cells treated with
50nM Adriamycin compared to the control cells received the same treatment.
We next explored the molecular mechanism underlying the functional role of
Rac1 dysregulation. For the study, we analyzed several Rac1-regulated oncogenic
pathways in the cells transduced with Rac1-shRNA versus control-shRNA-transduced
cells. As results shown in Figure 2.10, Rac1 knockdown substantially diminished the
phosphorylation of AKT at both T308 and S473 residues. Consistently, AKT downstream

26
target mTORC1 was also exhibited a decreased activity, as shown by diminution in
phosphorylation of RPS6 (Ribosomal protein S6). Because AKT activation is commonly
observed in MCL and considered as a core driven signaling, these data suggest that
Rac1 overexpression plays an important part in the development of MCL. In addition,
phosphorylation of RelA/p65 and ERK1/2, indicative of activation of these proteins, were
also decreased in the MCL cells upon Rac1 knockdown (Figure 2.10). Collectively, these
results suggest an important role for Rac1 overexpression in the hyper-activation of multiple oncogenic pathways in MCL.
Rac1 inhibition by NSC 23766 reduces viability of MCL cells and Rac1 overexpression rescue the inhibition effect of NSC 23766
To validate the effect of Rac1 inhibition, we used NSC 23766, a commonly used
specific Rac1 inhibitor55,61,62. Rac1 activity assay demonstrated that the EC50 (Inhibition
of Rac1 activity in cells by 50%) for NSC 23766 is approximate 25 μM (Figure 2.11). We
then treated Z138 and Mino cells with the drug. As shown in Figure 2.12A, the cell proliferation of both cell lines were substantially inhibited by NSC 23766 in dose dependent
manner within its linear dose range for Rac1 inhibition. Nevertheless, normal naïve B
cells were barely affected by NSC 23766 treatment, even at the 100 μM concentration
(Figure 2.12B). We also checked MCL cells death induced by NSC 23766. After treated
with NSC 23766, we observed significantly increased cell apoptosis by 25 μM and 50
μM (Figure 2.13). These results suggested that Rac1 targeting provides a specific toxic
effect toward only lymphoma cells, which is consistent with our previous results showing
that Rac1 was upregulated in MCL and involved in the activation of pro-survival oncogenic pathways.
Next, we overexpressed Rac1 in Z138, as well as JVM2 cells that express lower
level of both Rac1 and Rac1-GTP (Figure 2.14). The result showed that Rac1 overex-
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pression substantially rescued the cells from the inhibitory effect of NSC 23766 (Figure
2.15 A-B). These results further supported the pro-tumor role of Rac1 and targeting
Rac1 provides a specific toxic effect toward MCL lymphoma cells.
We next examined the effect of NSC 23766 on the major oncogenic signaling
pathways downstream of Rac1. As shown in Figure 2.16, similar to the effect of Rac1
knockdown by shRNA, inhibition of Rac1 by NSC 23766 in Z138 and Mino cells markedly reduced the pathway activities of AKT/mTORC1 [p-AKT (T308), p-AKT (S473), pPRS6 (S235/S236) and p-4E-BP1 (T37/T46)], NF-κB [P65 (S536)] and ERK [ER1/2
(T202/T204)] following treatment with NSC 23766. Together, these data validate the effect of Rac1 knockdown by shRNA and suggest a role for Rac1 in promoting tumor progression in MCL.
Inhibition of Rac1 by NSC 23766 enhances cytotoxic effect of Adriamycin in MCL
cells
In view of chemotherapy by Adriamycin being the standard approach to treat
MCL, we test the effect of Rac1 inhibition on the cytotoxic effect of Adriamycin in MCL
cells. Z138 and Mino cells were treated with Adriamycin and NSC 23766, individually or
in combination. Cell viability assay showed that the inhibition of Rac1 by NSC 23766
significantly increased the cytotoxic effect of Adriamycin especially after 72h of treatment
(5.65 ± 0.05 vs 3.12 ± 0.02, p=0.007 for Mino; 10.8 ± 0.38 vs 4.2 ± 0.07, p<0.001 for
Z138), although synergy of two drugs was not observed (Figure 2.17A). We also assessed the effect of Rac1 inhibition on apoptosis induction following Adriamycin treatment. For Z138 cells, combination of 10 µM NSC and 25 nM Adriamycin induced apoptosis approximately twice than that by single Adriamycin treatment (10.05 ± 0.05 vs 23.7
± 1.3, p=0.009; Figure 2.17B). For Mino cells, combination of 25 µM NSC 23766 and 75
nM Adriamycin induced 20% more cell apoptosis than that by individual Adriamycin
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treatment (34.6 ± 3.4 vs 58.1 ± 0.5, p=0.02; Figure 2.17B). These data suggests that
Rac1 inhibition could increase the cytotoxic effect of Adriamycin, further supporting its
application in clinical practice.
Rac1 is overexpressed in other B-cell lymphoma cell lines and inhibiting Rac1
could diminish cell viability of those lymphoma cell lines
As we known that various dysfunctional survival pathways, like PI3K/AKT/mTOR
and NF-B, has been demonstrated in DLBCL and BL. Rac1 positively regulated AKT,
ERK and NF-B pathways, which were confirmed in our previous result. To determine if
inhibition of Rac1 induced some tumor suppression effect in other lymphomas, we
checked Rac1 expression in other B-cell lymphoma cell lines. Two ABL-DLBCL (Ly3 and
TMD8), two GCB-DLBCL (DHL16 and Ly19) and two BL (Daudi and GA10) cell lines
were chosen. Western blot showed increased Rac1 protein level in all six lymphoma
cells (Figure 2.18).
Next, to identify the role of overexpressed Rac1 signaling in other lymphomas,
Rac1 siRNA was used to knock down Rac1 in DLBCL and BL cell lines. Three cell lines
we chose here were TMD8, Ly19 and Daudi cells that all have high expressed Rac1 protein level (Figure 2.18). Knockdown efficiency of siRNA reached over 50% in all cell lines
(Figure 2.19A). Notably, Rac1 knockdown significantly decreased cell viability in all three
cell lines compared to their respective controls (6.86 ± 0.10 vs 4.44 ± 0.27 for Daudi at
72h, p<0.001; 7.70 ± 0.17 vs 3.97 ± 0.08 for TMD8 at 72h, p<0.001; 8.27 ± 0.02 vs 5.86
± 0.08 for Ly19 at 72h, p<0.001, Figure 2.19B). Rac1 inhibitor, NSC 23766, was further
used here to treat those three cells. Our data showed that at 1μM and 10 μM NSC
23766 significantly inhibited the cell viability of lymphoma cells (Figure 2.20).
Molecular mechanism was further explored. Similarly, Rac1 knockdown substantially diminished the phosphorylation of AKT at both T308 and S473 residues. Consist-
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ently, AKT downstream target mTORC1 was also exhibited a decreased activity, as
shown by diminution in phosphorylation of RPS6. In addition, phosphorylation of
RelA/p65, indicative of activation of NF-κB pathway, was also decreased in the lymphoma cells upon Rac1 knockdown (Figure 2.21). These results gave us an initial concept
that Rac1 signaling could be a potential target in the DLBCL and BL system.
DISCUSSION
The study of MCL, including multi-disciplinary research from molecular biology to
the clinic, has improved the understanding of the MCL pathogenesis and given a new
sight to design novel clinical therapeutic strategies. However, it is still a challenge to define a standard therapy because of the heterogeneous biology and clinical presentation
of MCL patients. Thus, there is a critical need for a clear understanding of the pathogenic mechanisms of MCL in order to identify attractive and promising targets.
Rac1 has been defined as an oncogene for more than a decade with most of the
studies focusing on solid tumor63-65. In this study, we demonstrate that Rac1 protein is
aberrantly overexpressed in primary MCL tumors and established MCL cell lines (see
Figure 1). Importantly, high Rac1 protein level is correlated with poor overall survival of
MCL patients (see Figure 1h), making the examination of Rac1 level valuable in prognosis prediction. Immunohistochemical staining is a practical way to evaluate the expression level of Rac1, however, due to the limited number of cases being included in current
study, the significance of the Rac1 positive proportion and intensity have not been well
characterized. Further study involving larger cohorts of cases are encouraged to delineate Rac1 expression with disease progression in more detail.
Gene rearrangement involving Cyclin D1 is the hallmark of MCL. However, it has
demonstrated that simple Cyclin D1 overexpression is insufficient to induce the onset of
MCL tumor26, raising the importance of other mechanisms in MCL. Consistently, several
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core oncogenic pathways including AKT and NF-κB signaling have been found to be
dysregulated without correlated genomic aberration in MCL, which implies an interactive
activation of pathway network in cancerous state. In this study, we demonstrate that
Rac1 is directly associated with the activation of several oncogenic pathways in MCL,
suggesting that it locates at the central zone of pathway network, although the mechanism underlying Rac1 overexpression in MCL remains unclear. Previous studies have
demonstrated that endogenous Rac1 is activated by the BCR signaling and is required
for the activation of BCR subsequent signal transduction66,67. Considering the constitutive activation of the BCR signaling in MCL68 and its wide connections with other oncogenic pathways, it is likely that Rac1 plays an important role in mediating both of the tonic and chronic activating signals for MCL cells. Future studies are expected to elucidate
the Rac1 regulation network and its significance in signaling integration.
We found that the inhibition of Rac1 brought about only cytostatic effect. This is
in agreement with the defect of the pro-apoptotic machinery in MCL, such as BCL-2 and
MCL1 overexpression, that simple inhibition of common oncogenic pathways is insufficient to induce apoptosis. Notably, inhibition of Rac1 either by shRNA or NSC 23766
significantly enhanced the cytotoxic effect of Adriamycin (see Figure 2 & 4), potentiating
the combination of Rac1 inhibition with standard chemotherapy in MCL treatment. In the
current study, we tested the Rac1 specific inhibitor NSC 23766 in MCL cells, which
showed remarkable inhibition on cell viability upon single drug treatment and increased
apoptosis when combined with Adriamycin. Although the high effective dose (micromolar range) of NSC 23766 may impede its application in clinical practice, the data obtained with it provides evidence supporting a proof-of-concept to this hypothesis, which
will be tested upon new Rac1 inhibitors with improved EC50 become available.
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Moreover, we did some initial study of Rac1 in other aggressive B-cell lymphomas, like DLBCL and BL. Overexpressed Rac1 was also been found in other lymphoma
cell lines. In addition, inhibition of Rac1, either by siRNA or specific inhibitor, brought cytostatic role in those lymphoma cells. The possible explanation is that the downstream
pathways of Rac1, AKT and NF-κB pathways are well-known oncogenic pathways in
lymphomas. Further studies are needed to present the solid evidence on the potential of
inhibiting Rac1 in lymphoma treatment.
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Figure
Figure 2.1 Expression of Rho GTPases in human primary MCL tumors.
(A) mRNA Expression of all Rho GTPases members in human primary MCL tissues from
the LLMPP database. (B) Relative mRNA expression level of each Rho GTPase in MCL
cases compared with in naïve B cell, shown in fold changes. (C) Analysis of Rac1 mRNA
level in human primary MCL tissues from the LLMPP database. Expression levels are
the values of probes in affymetrix HG-U133-plus 2.0 arrays. Data are shown as mean ±
SEM. P value was calculated using the two-tailed student’s t test. * indicates P < 0.05.
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Figure 2.2 Expression of Rho GTPases in 64 online MCL cases.
Relative mRNA expression level of each Rho GTPase in MCL cases compared with in
naïve B cell, shown in fold changes. Expression levels are the values of probes in affymetrix HG-U133-plus 2.0 arrays.
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Figure 2.3 Rac1 is overexpressed in MCL cell lines.
(A) Rac1 mRNA level in MCL cell lines and naïve B cells. (B) Upper panel: Rac1-GTP,
Rac1-total and β-actin protein expression in MCL cell lines was analyzed by western blot;
lower panel: quantification of Rac1 protein level by Odyssey CLx system (LI-COR). The
calculation is based on the ratio between Rac1 signal and that of β-Actin. The experiments were repeated three times, and an average ration to that of the naïve B cells is
shown.
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Figure 2.4 Representative images of the IHC staining of Rac1 in tissues.
Representative images of Rac1 IHC staining in tonsil tissues (A) and negative staining
(B). (C and D) Representative image of Rac1 IHC staining in MCL case tissues. W=
weak Rac1 staining, S= strong Rac1 staining.
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Figure 2.5 Association of Rac1 protein level with overall survival (OS) in MCL patients.
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Figure 2.6 Positive correlation was existed between Rac1 mRNA expression and
proliferation rate in primary MCL tumors.
41 MCL cases with GEP data were divided into three groups by Rac-1 mRNA expression. Heat map illustrated the proliferation signature of Rac1-lower and higher mRNA
expression cases.
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Figure 2.7 Knocking down of Rac1 in two MCL cell lines.
Rac1 was knocked down by Dox inducible shRNA in Z138 cells (A) and Mino cells (B).
The protein level was determined by western blot after 24h of 1 μg/ml Dox treatment.
The relative Rac1 levels in the Dox treated samples were determined by normalization of
the Rac1 levels with their respective β-Actin levels.
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Figure 2.8 Rac1 promotes cell proliferation and survival in MCL.
Cell viability of Rac1 knockdown Z138 (A), Mino (B) cells and vector control cells were
determined for 3 days by Presto Blue cell proliferation assay. Define the cells number of
each group on day 0 as 1 and the y-axis stands for the increased folds of cell numbers
on each day compared to the day 0. The experiments were repeated three times in four
replicates with similar results obtained. Data shown are the average of three experiments and are presented as mean ± SEM. P value stands for the difference between
Rac1 shRNA Dox (+) and control Dox (+). **, P≤0.01; ***, P≤0.001.
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Figure 2.9 Rac1 knocking down increases the toxicity of Adriamycin in MCL.
Z138 (A) and Mino cells (B) transduced with Rac1-shRNA or control-shRNA were treated with 1 g/ml of Dox for 24h, and then treated with increasing concentrations of Adriamycin for 48h. Apoptosis was determined by Annexin V and 7-AAD staining followed by
flow cytometry measurement. The experiments were repeated three times with similar
results obtained. Data shown are the average percentage of three experiments and are
presented as mean ± SEM. P value stands for the difference between Rac1-shRNA Dox
(+) and control Dox (+). *, P≤0.05; **, P≤0.01; ***, P≤0.001.
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Figure 2.10 Pathway changes in Rac1 knocking down MCL cells.
Rac1-shRNA expressing and control cells were examined for phosphorylation of AKT,
RPS6, NF-B (p65), ERK1/2 and β-Actin by immunoblotting after 24h Dox induction. Ctr,
control.
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Figure 2.11 EC50 of Rac1 inhibitor, NSC 23766, in MCL cell line.
Mino cells were treated with NSC 23766 at the indicated concentrations for 2h. Cell lysates were subjected to Rac1 activity assay as described in Materials and Methods.
Relative Rac1 activity in each sample is calculated by normalizing the Rac1-GTP level
with total Rac1 level.
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Figure 2.12 Inhibition of Rac1 by NSC 23766 induces cytostatic effect in MCL cells.
(A) Z138 and Mino cells were treated with NSC 23766 at indicated concentrations for 3
days and assessed for cell proliferation by Presto Blue assay. Define cells number of
each group on day 0 as 1 and Y-axis stands the increased folds of cells number on day
3 compared to the day 0. (B) Naïve B cells were treated with 100 µM NSC23766 for the
indicated number of days and cell growth was determined by Presto Blue assay. Define
cells number of each group on day 0 as 1 and Y-axis stands the increased folds of cells
number on each day compared to the day 0. The experiments were repeated three times
in four replicates with similar results obtained, and an average Presto Blue fluorescence
unit is shown. PFUs: Presto Blue fluorescent units.
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Figure 2.13 NSC 23766 induced cell apoptosis in MCL cell lines.
Z138 and Mino cells were treated with increasing concentrations of NSC 23766 for 48h.
Apoptosis was determined by Annexin V and 7-AAD staining followed by flow cytometry
measurement. The experiments were repeated three times with similar results obtained.
Data shown are the average percentage of three experiments and are presented as
mean ± SEM.
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Figure 2.14 Overexpression of Rac1 in MCL.
Exogenous Rac1 was transfected by pcDNA3-EGFP-Rac1-wt in Z138 and JVM2 cells.
The protein level was determined by Western blot. The relative Rac1 levels in the Rac1
vector transfected cells were determined by normalization of the Rac1 levels with their
respective β-Actin levels.

59

60
Figure 2.15 Overexpression of Rac1 could partially rescue the cytotoxic effect of
NSC 23766.
Cell viabilities of Rac1 overexpressed Z138 cells (A) and JVM2 cells (B) and vector control cells were determined for 3 days after treated with NSC 23766 at indicated concentration by Presto Blue cell proliferation assay. Define the cells number of each group on
day 0 as 1 and the y-axis stands for the increased folds of cell numbers on the 3rd day
compared to the day 0. The experiments were repeated three times in four replicates
with similar results obtained. P value stands for the difference between Rac1 transfected
group and control group upon NSC 23766 treatment. **, P≤0.01; ***, P≤0.001.
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Figure 2.16 Oncogenic pathway changes upon NSC 23766 treatment in MCL.
Z138 and Mino cells were treated with 50 µM NSC 23766 for the indicated time and followed by Western blot analyses for the indicated protein phosphorylation and total levels.
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Figure 2.17 Inhibition of Rac1 by NSC 23766 enhances the cytotoxic effect of Adriamycin.
Z138 (A) and Mino (B) cells were treated with NSC 23766 and/or Adriamycin for 48h and
apoptosis determined by Annexin V and PI staining, as described in Materials and Methods. The experiments were repeated three times with similar results obtained. Data
shown are the average of three experiments and are presented as mean ± SEM. *,
P≤0.05; **, P≤0.01.
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Figure 2.18 Rac1 is overexpressed in other lymphoma cell lines.
Upper panel: Rac1-total and β-Actin protein expressions in ABC-DLBCL, GCB-DLBCL,
BL cell lines and normal B cells were analyzed by western blot; lower panel: quantification of Rac1 protein level by Odyssey CLx system (LI-COR). The calculation is based on
the ratio between Rac1 signal and that of β-Actin. The experiments were repeated three
times, and an average ration to that of the normal B cells is shown.
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Figure 2.19 Rac1 knockdown induced cytostatic effect in DLBCL and BL cell lines.
(A) Rac1 was knocked down by siRNA in Daudi, TMD8 and Ly19 cell lines. The protein
level was determined by western blot after 48h of siRNA transfection. The relative Rac1
levels in the siRNA samples were determined by normalization of the Rac1 levels with
their respective β-Actin levels. (B) Cell viability of Rac1 knockdown cells and control cells
were determined for 3 days by Presto Blue cell proliferation assay. Define the cells number of each group on day 0 as 1 and the y-axis stands for the increased folds of cell
numbers on each day compared to the day 0. The experiments were repeated three
times in four replicates with similar results obtained. Data shown are the average of
three experiments and are presented as mean ± SEM. P value stands for the difference
between Rac1 siRNA and control. ***, P≤0.001.
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Figure 2.20 Inhibition of Rac1 by specific inhibitor, NSC 23766, induces cytostatic
effect in DLBC and BL cell lines.
Ly19, TMD8 and Daudi cells were treated with NSC 23766 at indicated concentrations
for 3 days and assessed for cell viability by Presto Blue assay. Define cells number of
each group on day 0 as 1 and Y-axis stands the increased folds of cells number on day
3 compared to the day 0. The experiments were repeated three times in four replicates
with similar results obtained, and an average Presto Blue fluorescence unit is shown.
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Figure 2.21 Pathway changes in Rac1 knockdown DLBCL and BL cell lines.
Rac1-siRNA expressing and control cells were examined for AKT/mTOR, NF-κB (p65)
pathways and β-Actin by immunoblotting 48h after transfection. Ctr, control.
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Tables

Table 2.1. Rac1 protein expression in MCL tissues

IHC
Positive
(≥30%)

Negative
(<30%)

Percentage

Case number

>75%

6

55%-75%

6

30%-55%

6

<30%

14
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Chapter 3 Rac1-Pak2 axis is a potential therapeutic target in aggressive B-cell
lymphomas
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Summary
Previously, we demonstrated that Rac1 is a potential therapeutic target in MCL. However, it is hard to target Rac1, as a GTPase. PAKs are a family of serine/threonine protein
kinases comprised of six isoforms (PAK1-6). Only group I PAKs (Pak1, 2 and 3) are activated by Rac1. When activated by mutation, overexpression, or by upstream elements
such as Rac1, most PAK isoforms have oncogenic signaling effects in cells, including
the acquisition of growth signal autonomy, evasion of apoptosis, and promotion of invasion and metastasis. However, no study about PAKs has been done on hematological
malignancies. Here, we investigated the expression of PAKs in MCL. We found overexpressed Pak1 and Pak2 mRNA and protein level and highly activated Pak2 signaling in
MCL. Furthermore, we extended our studies to other aggressive B-cell lymphomas,
which showed the same results. To determine the significance of PAKs dysregulation in
aggressive B-cell lymphomas, we knocked down Pak1 and Pak2 separately in lymphoma cell liens using siRNA. The result shows that decreasing Pak2 level, not Pak1, in
cells significantly inhibited the cell proliferation. Consistently, inhibition of group I PAKs
using a specific inhibitor FRAX 597 in aggressive B-cell lymphomas cell lines showed a
similar cytostatic effect as Pak2 knockdown by siRNA. Moreover, synergistic effect was
observed between FRAX 597 and Adriamycin or ibrutinib in MCL cell lines. FRAX 597
could overcome the ibrutinib resistant in MCL and ABC-DLBCL resistant cell lines.
Mechanistic studies demonstrated that inhibition of Pak2, either by siRNA or chemical
inhibitor, substantially diminished the activity of signaling pathways downstream of Rac1Pak axis, including AKT/mTOR and NF-κB pathways. Collectively, the studies of the report suggest targeting Rac1-Pak2 could be a promising strategy in clinical treatment of
aggressive B-cell lymphomas.
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Introduction
The small GTPases RAS, Rac, Rho and CDC42 orchestrate many of the hallmarks of cancer. These proteins act as molecular switches existing in two conformational states, GDP and GTP bound. The exchange of GDP for GTP is accelerated by the
association of GEPs. RAS mutation disrupt the subsequent hydrolysis of GTP and cause
Ras to remain its activated GTP-bound state, are found in about 20% of tumors69. Upon
activation, small GTPases interact with downstream effectors to elicit their responses.
The p21-activated kinases (PAKs) are among the best characterized effectors of Rac
and CDC4270.
PAKs are a family of serine/threonine protein kinases comprised of six isoforms
(PAK1-6)71. By sequence and structure, the six mammalian PAKs can be categorized
into two subgroups: group I (PAK1-3) and group II (PAK4-6)72. All PAKs possess a conserved C-terminal serine/threonine kinase domain with a single phosphorylation site and
an N-terminal regulatory domain73. The regulatory domain of group I PAKs is structurally
distinct from that of group II PAKs, consistent with the different mechanisms regulating
activity of these proteins72.
Group I PAKs are thought to be regulated via a trans auto-inhibition mechanism.
The N-terminal p21-GTPases binding domain (GBD) overlaps with an autoinhibitory domain (AID)74. PAKs folds into an inactive homodimer, wherein the AID domain binds to
the kinase domain of its partner. Binding of active Rho GTPases such as CDC42 and
Rac1 to the GBD, and coincident binding of phosphoinositide to an adjacent segment
rich in basic amino acids, leads to dissociation of the AID from the kinase domain reorganization of the dimer and subsequent autophosphorylation. When the phosphorylated kinase domain binds to a substrate, it adopts a monomeric conformation. Subse-
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quent autophosphorylation at multiple sites stabilizes this catalytically active state. However, the mechanism of activation of group II PAKs is less clear. Unlike group I PAKs,
the kinase domain of the group II PAKs is constitutively phosphorylated. Hence, transition to the active form likely depends on conformational changes75. Currently, it was believed that the AID in the N-terminus that inactivates the kinase domain in cis, until binding of GRP-CDC4276.
Mounting evidence that cancer is a disease of dysregulated signaling pathways
has led to development of signaling-based targeted therapies for various human tumor
types. PAKs are positioned at the intersection of a number of signaling pathways required for oncogenesis. When activated by mutation, overexpression, or by upstream
elements such as Rac, most PAK isoforms have oncogenic signaling effects in cells, including the acquisition of growth signal autonomy, evasion of apoptosis, and promotion
of invasion and metastasis72,77. There is little evidence for cancer cells having activating
mutation in PAK genes although a mutation was found in the kinase domain of PAK4 in
a colorectal tumor sample71. However, PAK family members are amplified, overexpressed or hyper-activated in a number of human tumors. Moreover, several distinct molecular mechanisms caused aberrant PAK signaling in cancer, including gene amplification and alteration of upstream regulators, such as Rac1. Studies have shown that in
most cell types, PAK isoforms promote cell cycle progression when overexpressed and
hinder such progression when removed or inhibited78. The specific mechanism are understood in some detail, as PAKs activate components of the ERK, AKT and Wnt signaling pathways, all of which are closely tied to cell cycle progression. In addition, several
members of the PAK family have been shown to inhibit apoptosis. Some of these effects
are mediated by phosphorylation of BAD, which renders this protein unable to bind BCL2
and participate in apoptotic signaling. It has been also shown that PAK activates the NF-
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κB pathway, which is relevant to several aspects of tumorigenesis, including cell survival,
angiogenesis and inflammation77.
All those data with regard to cancers is on the role of Pak1 in various solid tumor,
such as breast cancer and pancreatic cancer. No study about PAKs has been done on
hematological malignancies. Our previous studies showed Rac1 play a pathogenesis
role in MCL and could be a potential therapeutic target in treating MCL. In view of group
I PAKs are activated by Rac1, whereas group II PAKs are activated only by CDC42,
group I PAKs will be our focus in the following study. Moreover, considering that Pak3 is
preferentially expressed in neuronal cells and involved in synapse formation79,80, Pak1
and Pak2 will be our emphases of this Chapter. Furthermore, we extended our study to
the other aggressive B-cell lymphomas in this Chapter.
RESULTS
PAKs is overexpressed and activated in aggressive B-cell lymphomas patient
samples and cell lines
By analyzing the GEP data of 41 MCL cases, we found that Pak1 and Pak2
mRNA are overexpressed in MCL samples, compared to Naïve B cells (p<0.005) (Figure
3.1A). Figure 3.1B showed Pak2 is the one who has the highest mRNA expression in
MCL for Group I PAKs. Next we examined protein levels of Pak1, Pak2 and its activation
in a panel of 6 MCL cell lines (Granta-519, Jeko-1, JVM2, Maver-1, Mino and Z138) and
two GCB-DLBCL cell lines (DHL16 and LY19), two ABC-DLBCL cell lines (LY3 and
TMD8) and two Burkitt lymphoma cell lines (Daudi and GA10). The result showed that,
while Pak1 is expressed at higher levels in 3 of the MCL cell lines (Granta 519, JVM2
and Z138) than in Naïve B cells (Figure 3.2), Pak2 is over-expressed in all MCL cell lines
compared to the normal control Naïve B cells (Figure 3.2). Moreover, we observed a re-
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markably higher expression of p-Pak2 level in two active phosphorylation sites (Ser141
and Thr423), but not p-Pak1 level, in all MCL cell lines than in normal naïve B cells. In
DLBCL cell lines and Burkitt lymphoma cell lines, we observed the similar phenomenon,
that remarkably expressed Pak1, Pak2 protein and highly activated Pak2 signaling (indicated by increased phosphorylated level) was existed compared with normal B cells
(Figure 3.3). All those data indicated that constitutively expressed and activated Pak2
signaling was existed in aggressive B-cell lymphomas.
To confirm the up-regulation of PAKs, we performed IHC analysis of PAKs in one
MCL TMA and two DLBCL TMAs. We observed negative staining of Pak1 in both MCL
and DLBCL tissues (Figure 3.4A). However, over-expressed Pak2 protein was found in
both MCL and DLBCL cases shown in Figure 3.4B. We also observed strong p-PAK
staining in our lymphoma tissues (Figure 3.4C). Considering that p-Pak2 level is so
much higher than p-Pak1 in our previous western blot experiment, we can assume that
strong p-PAK staining was mainly due to the high level of p-Pak2 level in lymphoma tissue. All these IHC results pointed out that Pak2 signaling is constitutively expressed and
activated in lymphoma tissues, and highly activated Pak2 signaling may play a tumorigenesis role in lymphoma.
Knockdown of Pak2, not Pak1, inhibits the proliferation and induces cytostatic effect in aggressive B-cell lymphomas through inhibiting various downstream oncogenic targets
To determine the specific role of Pak1 and Pak2 in MCL and who is the major
one contributing transmitting Rac1 signaling in MCL, we transfected Z138 cell line, which
expressed high level of Pak1 and Pak2, with Pak1 and Pak2 siRNA respectively. We
observed the knockdown efficiency reached over 50% in Z138 cells for each siRNA
(Figure 3.5 A-B). Notably, knockdown of Pak2 significantly decreased cell proliferation in
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Z138 cells compared to the control group (9.49 ± 0.27 vs 5.93 ± 0.23 for siRNA1, 5.19 ±
0.29 for siRNA2 at 72h, p<0.001, Figure 3.6A). However, Pak1 knockdown did not induce any cytostatic effect in Z138 cells (7.24 ± 0.19 vs 6.90 ± 0.32 for siRNA1, 6.84 ±
0.05 for siRNA2 at 72h, p>0.05, Figure 3.6B). These data gave us a hint that Pak2 might
be the one who contributed to transmit activated Rac1 signaling in MCL system. To explore the dysregulated pathway changes in Pak2 knockdown cells and confirm the role
of PAKs in transmitting Rac1 activated signaling, we checked the well-studied Rac1
downstream pathways mentioned previously. As results shown in Figure 3.7A, Pak2
knockdown substantially diminished the activation of AKT/mTORC1 pathway, as shown
by diminution in phosphorylation of AKT at both T308 and S473 residues, and p-RPS6 in
Z138 cells. In addition, p-P65 was also decreased in Pak2 knockdown Z138 cells, which
indicated the decreased activation of NF-κB signaling. However, there is no obvious
pathway changes in Pak1 knockdown Z138 cells (Figure 2.7B). These results indicated
that the function role of Rac1 is mainly through Pak2, not Pak1, and Rac1-Pak2 play a
tumorigenesis role by affecting various oncogenic pathways in MCL.
We also did the same knockdown study on other lymphoma cell lines, ABCDLBCL cell line TMD8, GCB-DLBCL cell line Ly19 and BL cell line Daudi. Transfection
induced the knockdown efficiency reaching over 50% in three cell lines for each siRNA
(Figure 3.8 A-B), excepting Pak2 siRNA2 in Ly19 cells, which was not working very efficiently (Figure 3.8A). For the cell viability study, similarly we observed that Pak2 knockdown (9.32 ± 0.11 vs 5.39 ± 0.23 for siRNA1, 5.81 ± 0.07 for siRNA2 at 72h in Daudi,
p<0.001; 8.67 ± 0.20 vs 4.34 ± 0.22 for siRNA1, 4.19 ± 0.15 for siRNA2 at 72h in TMD8,
p<0.001; 8.52 ± 0.08 vs 6.45 ± 0.07 for siRNA1, P=0.009, 8.32 ± 0.08 for siRNA at 72h
in Ly19, p>0.05, Figure 3.9A), not Pak1 knockdown (Figure 3.9B), remarkably inhibited
the lymphoma cells growth. This result confirmed the pro-survival role of Pak2 in lym-
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phoma system. Western blot also showed that Pak2 knockdown decreased the activation of Akt-mTORC1 and NF-κB signaling pathways (Figure 3.10). Above results indicated that in lymphoma system, Pak2 is the major one who transmitting activated Rac1 signaling and contribute to the lymphoma survival through activating various pro-survival
oncogenic pathways.
PAKs inhibition by chemical inhibitor leads to inhibition of MCL cell proliferation
and acts synergistically with Adriamycin treatment
Knockdown of Pak2 results in the inhibition of lymphoma cell growth and multiple
downstream targets. There are several PAKs-inhibitors available for studies. FRAX 597
is a potent group I PAKs inhibitor81. Therefore, we determined whether we could achieve
the growth inhibition and blockage of the downstream targets of Pak2 in aggressive B
cell lymphoma with FRAX 597.
MCL cell lines, Z138 and Mino, were treated with FRAX 597 at different concentrations and cultured for 3 days, cell viability was detected on day 3. We observed significantly decreased cell viability in both cell lines when treated with Pak inhibitor at 1μM
(Figure 3.11A-B). Previously, we demonstrated that Rac1 could sensitize the cytotoxicity
of chemo-drug Adriamycin. Here, we further treated Z138 and Mino with Adriamycin
combined with FRAX 597. Not surprisingly, we observed synergistic effect between
Adriamycin and FRAX 597 shown by combination index (CI) level lower than 1 (Figure
3.11 A-B). We also detected the apoptosis in combination of FRAX 597 500 nM with
Adriamycin 12.5 nM. Western blot showed significantly increased cleaved-caspase 3
level in combination group compared with single drug alone (Figure 3.11C).
To further confirm the pathway changes upon Pak2 inhibition, Mino cells and
Z138 cells were harvested after 24h treatment by 1 μM FRAX 597 and western blots
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were performed. FRAX 597 treatment inhibited the phosphorylation of AKT and
mTORC1 downstream targets, RPS6 and 4E-BP1. We also observed a downregulation
of the phosphorylation of p65 (NF-κB pathway), p42/44 (ERK pathway) (Figure 3.12). All
those pathways are supposed to play an important role in promoting cell proliferation
and inhibiting apoptosis. In addition, a decreased cyclin D1 level was found after FRAX
597 treatment (Figure 3.12). These data are consistently with previous knockdown results and further confirmed the pathogenic role of Rac1-Pak2 pathway in MCL.
FRAX597 leads to inhibition of DLBCL and BL cell viability
Furthermore, we did the same study on other B cell lymphomas, such as DLBCL
and BL. Not surprisingly, we observed the remarkably proliferation-inhibition effect of
FRAX597 in LY3 and TMD8 cell lines, DHL16 and Ly19 cell lines, Daudi and GA10 cell
lines (Figure 3.13). Specifically, 1μM FRAX 579 almost stop the lymphoma cells proliferation (Figure 3.13).
Synergistic effect was found between FRAX 597 and ibrutinib in Ibrutinib sensitive
MCL cell lines and FRAX 597 could overcome ibrutnib resistant in resistant MCL
cell lines
In the treatment of refractory MCL, promising results have been achieved with ibrutinib82-84. However, the biggest problem for ibrutinib in the clinic scenario is drug resistant. Moreover, ibrutinib resistant usually means potentially untreatable. Studies
showed that sustained PI3K-AKT activity and activation of the alternative NF-κB signaling pathway can lead to primary or secondary resistance to ibrutinib85. As PAK inhibition
resulted in the suppression of multiple oncogenic pathways including AKT/mTOR and
NF-κB signaling pathways, we questioned whether resistance to ibrutinib could be overcome by FRAX 597 treatment, and if there is synergistic effect between ibrutinib and
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FRAX 597 treatment in MCL. We chose four MCL cell lines whose resistance to ibrutinib
is known and shown in table 3.1: Mino and Maver-1 (which are responsive to ibrutinib),
Z138 (with a TRAF2 mutation contributing alternative NF-κB activation86) and JVM2
(which are resistant to ibrutinib). Cells were treated with escalating doses of ibrutinib and
FRAX 597 for 72h and Presto Blue assays were performed. We observed a synergistic
effect existed in Mino cells with CI values less than 0.3 (Figure 14A) and in Maver-1 cells
(Figure 14B) with CI values less than 0.4 in all combination groups. Additionally, resistance to ibrutinib could be overcome by combined with FRAX 507 shown by CI values
less than 0.7 in JVM2 cell line (0.23 for the last combination group) (Figure 3.15A); CI
values less than 0.9 for the first two combination groups and less than 0.2 for the last
combination group in Z138 cell line (Figure 3.15B).
FRAX 597 could overcome ibrutnib resistant in resistant ABC-DLBCL cell lines
Ibrutinib has also been widely used in ABC-DLBCL87. However, MYD88TIR mutations
(not combined with CD79 A/B mutations) contribute to the primary resistance to ibrutinb
in ABC-DLBCL88. To testify if resistance to ibrutinib could be overcome by combined with
FRAX 597 in ABC-DLBCL, two iburutinib resistant cell lines, Ly187 and Ly333, were chosen. We observed a synergistic effect at some combination conditions in those two cell
lines (Figure 3.16). Specifically, for Ly3 cell line we observed synergistic effect on all
combination groups with CI value less than 0.5 (Figure 3.16A). For Ly1 cells, synergistic
effect happened on 0.5+0.1, 1+1 and 2+2 combination groups with CI value less than
0.71 (Figure 3.16B). These results indicated that resistance to ibrutinib could be overcome by combined with PAKs inhibitor in ABC-DLBCL.
DISCUSSION
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DLBCL and MCL are aggressive subtypes of NHL with diverse clinical and molecular characteristic. Significant proportions of DLBCL and almost all patients with MCL
ultimately develop resistant disease. Introduction of rituximab (R) to the standard CHOP
regimen in DLBCL and MCL has significantly improved outcomes89. However, patients
with high-risk disease continue to have unfavorable outcomes, underscoring the biologic
heterogeneity of this disease. There is a critical need for a clear understanding of the
pathogenic mechanisms of DLBCL and MCL in order to identify attractive and promising
targets.
Our previous study has identified aberrantly over-expressed Rac1 in MCL cases
and cell lines, and the overexpression correlated with higher proliferation rate and poor
prognosis of MCL patients. In addition, Rac1 inhibition by shRNA or inhibitor significantly
decreased MCL cell proliferation and increased the cytotoxicity of chemo-drug Adriamycin. We also extended Rac1 study to DLBCL and BL. Similar results indicated that Rac1
also contribute to the dysregulated oncogenic pathways in DLBCL and BL, and play a
tumorigenesis role. However, Rac1 is a member of Rho GTPase, which is hard to target.
There is no potent Rac1 specific inhibitor that can be used in further in vivo study. Studies have showed that PAKs are among the best-characterized effector of Rac1. Therefore, we are trying to identify if activated Rac1 signal is through PAKs and targeting
PAKs might be a better choice.
PAK serine/threonine kinases have recently been found to be key regulators of
cancer-cell signaling networks90. They exert regulatory control over essential biological
processes. For group I PAKs, Pak1 is the most established isoform in human cancers,
like breast cancer91, colon cancer92, and ovarian cancer93. The roles of Pak2 are beginning to be discovered. In our study, we demonstrated that Pak2 protein were aberrantly
overexpressed in primary MCL and DLBCL tumors and established MCL and DLBCL
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cell lines. Moreover, highly activated Pak2 were found in both MCL, DLBCL cell lines
and clinical cases shown by overexpressed phosphorylation level of Pak2. All these indicated that hyper-activated Rac1-pak2 signaling are existed in aggressive B-cell lymphomas.
Gene rearrangement is a hallmark of lymphoma, such as involving Cyclin D1 is
the hallmark of MCL94, involving MYC is the hallmark of BL95. However, it has been
demonstrated that Cyclin D1 overexpression alone is insufficient to induce the onset of
MCL, raising the importance of other mechanisms in MCL lymphomagenesis. Aberrant
activities of PI3K/AKT/mTOR and NF-κB pathways have been reported in various types
of B-cell neoplasms96. Constitutively activation of NF-κB has frequently been observed in
follicular lymphoma, DLBCL, mucosa-associated lymphoid tissue (MALT) lymphoma,
multiple myeloma and MCL, as well as MCL cell lines97, in which inhibition of this constitutive activation induces growth arrest and apoptosis. Activation of PI3K/AKT/mTOR
pathway98 is one of the most common defects in human malignancies, including BL,
MCL and Hodgkin’s lymphoma. The repeated discovery of the involvement of NF-κB and
PI3K/AKT/mTOR in distinct forms of B-cell neoplasia underscores the importance of
these signaling pathways in B-cell transformation. Additionally, evidences showed that
NF-κB and PI3K pathways are interconnected in various lymphoma models, such as
iMycEµ B cell lymphoma99. Signaling through each of these molecules is required for tumor maintenance and Myc expression, and combined inhibition results in additive suppression of tumor growth. In this study, we demonstrated that Pak2 is directly associated
with the activation of several pro-survival oncogenic pathways mentioned above in MCL,
as well as in DLBCL and BL, suggesting that it locates at the central node of pathway
network. Moreover, these pathways have also been demonstrated as the downstream
pathways of Rac1, which means that Pak2 functioned as transmitting activated Rac1
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signal in aggressive B-cell lymphomas. This indicated that inhibiting Rac1-Pak2 axis
could be a way to inhibit lymphoma by shutting down constitutively activated various oncogenic pathways all at once.
Not surprisingly, we found that the inhibition of Pak2, not Pak1, brought about a
cytostatic effect, which consistent with the above pathway changes. Notably, inhibition of
Pak2 either by siRNA or by specific inhibitor FRAX 597 significantly inhibited cell growth
of MCL cell lines, also DLBCL and BL cell lines. As we known, ibrutinib, available BTKinhibitor, could achieve significant efficacy in the treatment of refractory or relapsed MCL.
However, somatic mutations in NF-κB regulatory genes can confer resistance to ibrutinib
treatment in MCLs100. Interestingly, Pak2 inhibition resulted in the inhibition of the NF-κB
signaling pathways not only in the MCL cell lines Mino, but also in Z138, which has a
known TRAF2 mutation (contribute to the Ibrutinib resistant). Combined treatment of ibrutinib and FRAX 597 turned out to be synergistic and ibrutinib resistance in Z138 and
JVM2 cells could be overcome by FRAX 597 through inhibition of the NF-κB signaling
pathway. For ABC-DLBCL, constitutive activation of BCR leads to activation of the NFκB pathway via a cascade of kinases, such as SYK, BTK, protein kinase C-β (PKCβ)101.
Inhibition of BTK with ibrutinib has demonstrated an overall response rate of 41% in
ABC-DLBCL. However, patients with CD79BWT and MYD88mut or CARD11mut did not respond to ibrutinib, indicating the need for therapies targeting BCR-independent activation of NF-κB induced by these mutations. Our results showed FRAX 597 could overcome ibrutinib resistance in two ibrutinib-resistant ABC-DLBCL cell lines, Ly3 and Ly1.
This conclusion indicated that PAK inhibition could be a potential therapeutic approaches that can combined with ibrutinib in MCL and ABC-DLBCL patients. Moreover, FRAX
597 combined with another chemo-drug Adriamycin also induced synergistic effect in
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MCL. All these results indicated the potential of PAK inhibitor as combination treatment
agent in the future study.
In summary, Pak2 inhibition by siRNA and inhibitor demonstrated promising antitumor growth activities in MCL, DLBCL and BL cells. The potential mechanism is Pak2
inhibition leads to significant inhibition of two important survival pathways: the PI3K/AKT
and NF-κB pathways, which are the two most important survival pathways in aggressive
B-cell lymphomas. PAK inhibitor combined with ibrutinib or Adriamycin induced synergistic effect in MCL. Furthermore, PAK inhibitor could overcome ibrutinib resistant in resistant MCL and ABC-DLBCL cell lines. Therefore, a molecularly based clinical exploration of FRAX 597 in combination with standard of care chemotherapy, ibrutinib, or other
targeted therapies is a promising combination therapeutic approach for the treatment of
aggressive B-cell lymphomas.
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Figure
Figure 3.1 Expression of PAKs in human primary MCL tumors.
(A) Analysis of Pak1 and Pak2 mRNA level in human primary MCL cases from the
LLMPP database. (B) mRNA expression of all group I PAKs members in MCL cases.
Expression levels are the values of probes in affymetrix HG-U133-plus 2.0 arrays. Data
are shown as mean ± SEM. P value was calculated using the two-tailed student’s t test.
** indicates P < 0.001.
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Figure 3.2 PAKs are overexpressed and constitutively activated in MCL cell lines.
Pak1, Pak2, p-PAKs and β-Actin protein expression in MCL cell lines was analyzed by
western blot.
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Figure 3.3 Over-expressed and activated Pak2 signaling in aggressive B-cell lymphomas cell lines.
Pak1, Pak2, p-PAKs and β-Actin protein expression in MCL cell lines was analyzed by
western blot.
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Figure 3.4 Representative images of the IHC staining of PAKs and p-PAK in tissues.
Representative images of Pak1 staining (A), Pak2 staining (B) and p-PAK staining in
MCL case tissues.
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Figure 3.5 Pak1 and Pak2 knocking down in Z138 cell line.
(A) Pak1 was knocked down by two different Pak1 siRNAs (siRNA 1 and 2) transfection
in Z138 cells. (B) Pak2 was knocked down by two different Pak2 siRNAs (siRNA 1 and 2)
transfection in Z138 cells. The protein level was determined by western blot 48h after
transfection. The relative Pak1 and Pak2 levels in the knockdown group were determined by normalization of the Pak1 and Pak2 levels with their respective β-Actin levels.
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Figure 3.6 Pak2 promotes cell proliferation and survival in MCL.
(A) Cell proliferation of Pak2 siRNAs group (siRNA1 and siRNA2) and control group in
Z138 cell line was determined for 3 days by Presto Blue cell proliferation assay. (B) Cell
proliferation of Pak1 siRNAs group (siRNA1 and siRNA2) and control group in Z138 cell
line were determined for 3 days by Presto Blue cell proliferation assay. Define the cells
number of each group on day 0 as 1 and the y-axis stands for the increased folds of cell
numbers on day 3 compared to the day 0. The experiments were repeated three times in
four replicates with similar results obtained. Data shown are the average of three experiments and are presented as mean ± SEM. P value stands for the difference between
Pak2 knockdown group and control group. ***P≤0.001.
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Figure 3.7 Pathway changes of Pak2 knockdown and Pak1 knockdown in MCL cell
line Z138.
Pak2-siRNA expressing and control cells (A), Pak1-siRNA expressing and control cells
(B) were examined for phosphorylation of PAKs, AKT, RPS6, NF-B (p65) and β-Actin
by immunoblotting 48h after transfection. Ctr, control.
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Figure 3.8 PAKs knocking down in DLBCL cell lines (TMD8 and Ly19 cell lines)
and BL (Daudi cell line).
(A) Pak2 was knocked down by two different siRNAs in Daudi, TMD8 and Ly19 cell lines.
(B) Pak1 was knocked down by two different siRNAs in TMD8 and Ly19 cell lines. The
protein level was determined by western blot 48h after siRNA transfection. The relative
Pak2 or Pak1 level in the knockdown group were determined by normalization of the
Pak2 or Pak1 level with their respective β-actin levels.

104

105
Figure 3.9 Pak2 knockdown, not Pak1 knockdown, induced inhibition of cell viability of DLBCL cell lines.
(A) Cell proliferation of Pak2 siRNAs group (siRNA1 and siRNA2) and control group in
TMD8, LY19 and Daudi cell lines were determined for 3 days by Presto Blue cell proliferation assay. (B) Cell proliferation of Pak1 siRNAs group (siRNA1 and siRNA2) and
control group in TMD8 and Ly19 cell lines were determined on day 3 by Presto Blue cell
proliferation assay. Define the cells number of each group on day 0 as 1 and the y-axis
stands for the increased folds of cell numbers on day 3 compared to the day 0. The experiments were repeated three times in four replicates with similar results obtained. Data
shown are the average of three experiments and are presented as mean ± SEM. P value
stands for the difference between Pak2 knockdown group and control group. ***P≤0.001.
**P≤0.01.
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Figure 3.10 Pathway changes in Pak2 knocking down aggressive B-cell lymphoma
cell lines.
Pak2-siRNA expressing and control cells were examined for phosphorylation of PAKs,
AKT, RPS6, NF-B (p65) and β-Actin by immunoblotting 48h after transfection. Ctr, control.
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Figure 3.11 Inhibition of Rac1 by FRAX 597 induces cytostatic effect in MCL cells
and synergistic effect was found between FRAX 597 and Adriamycin in MCL cell
lines.
Z138 (A) and Mino (B) cells were treated with FRAX 597 single drug, and combined with
Adriamycin, at indicated concentrations for 3 days and assessed for cell viability by
Presto Blue assay. Define cells number of each group on day 0 as 1 and Y-axis stands
the increased folds of cells number on day 3 compared to the day 0. The experiments
were repeated three times in four replicates with similar results obtained, and an average Presto Blue fluorescence unit is shown. PFUs: Presto Blue fluorescent units. Combination index (CI) between these two drugs was calculated by using Compusyc software. (C) Cells were treated with FRAX 597 at 500nM group, Adriamycin at 12.5 nM
group and combination group. Western blot showed the cleave-caspase 3 level in those
groups.
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Figure 3.12 Oncogenic pathway changes upon FRAX 597 inhibition in MCL.
Mino and Z138 cells were treated with 1 μM FRAX 597 for 24h and followed by Western
blot analyses for the indicated protein phosphorylation and total levels.
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Figure 3.13 Inhibition of PAKs by specific inhibitor, FRAX 597, induces cytotoxic
effect in DLBC and BL cell lines.
Ly19, TMD8 and Daudi cells were treated with FRAX 597 at indicated concentrations for
3 days and assessed for cell viability by Presto Blue assay. Define cells number of each
group on day 0 as 1 and Y-axis stands the increased folds of cells number on day 3
compared to the day 0. The experiments were repeated three times in four replicates
with similar results obtained, and an average Presto Blue fluorescence unit is shown.

114

FRAX 597 (uM)
Cell proliferation
(Folds of cell seeded)

10

0
0.125
0.25
0.5
1
2

8
6
4
2
0
Ly19

TMD8
Cell lines

Daudi

115
Figure 3.14 Synergistic effect was existed between FRAX 597 and ibrutinib in ibrutinib sensitive cell lines, Mino and Maver-1.
Mino (A) and Maver-1 (B) cells were treated with FRAX 597 or ibrutinib single drug and
combination at indicated concentrations for 3 days and assessed for cell viability by
Presto Blue assay. Define cells number of each group on day 0 as 1 and Y-axis stands
the increased folds of cells number on day 3 compared to the day 0. The experiments
were repeated three times in four replicates with similar results obtained. Combination
index (CI) between these two drugs was calculated by using Compusyc software.
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Figure 3.15 PAK inhibitor, FRAX 597, could overcome ibrutinib resistant in resistant MCL cell lines, JVM2 and Z138.
JVM2 (A) and Z138 (B) cells were treated with FRAX 597 or ibrutinib single drug and
combination at indicated concentrations for 3 days and assessed for cell viability by
Presto Blue assay. Define cells number of each group on day 0 as 1 and Y-axis stands
the increased folds of cells number on day 3 compared to the day 0. The experiments
were repeated three times in four replicates with similar results obtained, and an average Presto Blue fluorescence unit is shown. Combination index (CI) between these two
drugs was calculated by using Compusyc software.
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Figure 3.16 Synergistic effect was found between FRAX 597 and ibrutinib in ibrutinib-resistant ABC-DLBCL cell lines.
Ly3 (A) and Ly1 cells (B) were treated with FRAX 597 or ibrutinib single drug and combination at indicated concentrations for 3 days and assessed for cell viability by Presto
Blue assay. Define cells number of each group on day 0 as 1 and Y-axis stands the increased folds of cells number on day 3 compared to the day 0. The experiments were
repeated three times in four replicates with similar results obtained, and an average
Presto Blue fluorescence unit is shown. CI between these two drugs was calculated by
using Compusyc software.
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Tables

Table 3.1 IC50 of ibrutinib and resistant status in MCL cell lines

MCL cell lines

IC50 (uM)

Sensitive or resistant

Mino

0.1

Sensitive

Maver-1

0.1

Sensitive

Jeko-1

>10

Resistant

JVM2

>10

Resistant

Granta 519

>10

Resistant

Z138

>10

Resistant
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Chapter 4 Major conclusions and future directions
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Major conclusions
This dissertation describes the exciting discovery of highly activated Rac1-Pak2
axis and their tumorigenesis role in aggressive B cell lymphomas, including MCL,
DLBCL and BL. The function of Rho GTPase family member in lymphoma is not clear. In
Chapter 2, we did GEP in 41 MCL cases and analyzed the whole Rho GTPase members,
turned out Rac1 is the only GTPase that has a relatively higher mRNA expression in
MCL cases than in normal control naïve B cells. Further study confirmed the expression
in the protein level by showing that higher totoal-Rac1 level and Rac1-GTP expression in
MCL cases and cell lines than in normal control. In addition, Rac1 higher expression correlated with the higher proliferation rate of MCL cases and the poor overall survival in
MCL patients. The following functional study demonstrated that inhibiting Rac1 brought
out cytostatic effect in MCL cell lines, and sensitized the cytotoxicity effect of chemodrug. We also extended our Rac1 study to the DLBCL and BL. We demonstrated that
inhibiting Rac1 could also induce cytostatic effect by inhibiting various oncogenic pathways in DLBCL and BL.
In Chapter 3, we described the discovery of Pak2, not pak1, is the one that
passed the activated Rac1 signal to the downstream various oncogenic pathways in aggressive B cell lymphomas. Inhibiting Pak2 decreased the lymphoma cells viability by
diminishing the activation of AKT/mTOR and NF-κB pathways, which are well known as
two important survival pathways in aggressive B-cell lymphomas. Combination treatment
study demonstrated synergistic effect was existed between PAK inhibitor and ibrutinib or
Adriamycin in MCL cell lines and ibrutinib resistance could be overcome by combined
with PAKs inhibition in resistant MCL and ABC-DLBCL cell lines. In summary, we present a proof-of-concept that targeting Rac1-Pak2 axis might be a potential approach
used in combination treatment to treat relapsed and refractory MCL and DLBCL, two
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subtypes of NHL with AKT/mTOR and NF-κB pathways dysregulations, where PAKs inhibitor is therapeutically relevant.
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Future directions
Generate secondary resistant to ibrutinib in MCL and ABC-DLBCL cell lines and
identify the resistant overcome by PAKs inhibitor
Ibrutinib is a novel BTK inhibitor that has shown an unprecedented overall response rate and progression-free survival in relapsed/refractory MCL patients and in
ABC-DLBCL. Clinically, ibrutinib rapidly induced lymphocytosis and lymph node shrinkage. Unfortunately, despite the dramatic responses to ibrutinib, resistance inevitably develops. Approximately 43% of MCL patients have shown partial or complete lack of response to ibrutinib and experience disease progression within 12 months of treatment.
Our study has demonstrated that primary resistant to ibrutinib (JVM2, Z138, LY3 and
Ly1 cells) could be overcome by PAK inhibitor. In the future direction, we will determine
if PAK inhibition could overcome acquired ibrutinib resistant.
Two approaches will be used. Traditionally, acquired drug resistance would be
studied by chronically exposing cancer cell lines in vitro to increasing does of drug.
Therefore, firstly, we will generate acquired ibrutinib resistant Mino, Maver-1 and TMD8
cell lines. ABPP (activity-based proteomics) will be used to compare changes in relative
kinase activities between resistant cells and parental cells at a system level. Studies
have mentioned that BTK-independent kinases or BTK bypass pathways drive ibrutinib
resistant, such as PI3K-AKT-mTOR-related kinases. We will confirm this in our future
study and try to find more potential targeted kinases. PAKs inhibitor will be used to identify if PAKs inhibition could overcome the acquired ibrutinib resistance.
Secondly, drug resistance is heavily influenced by the extrinsic tumor microenvironment (TME). TME-mediated resistance is a form of de novo drug resistance that protects tumor cells from the effects of diverse therapies. Lymph node stromal cells (HK
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cells) and bone marrow stromal cells (HS5) will be used to co-culture with Mino, Maver-1
and TMD8 cell lines. ABPP will be used to examine the kinase response profiles in those
cells modulated by stroma. Combining the protein kinase reprogramming data of acquired drug resistance cells, a major kinase network can be formed. Moreover, this result can be instrumental in the identification of potential drug targets. Also, PAKs inhibitor
will be used here to determine if PAKs inhibition could improve resistance mediated by
lymphoma-stromal cell interactions.
Identification of Pak2-interacting protein profiles in MCL
To identify Pak2-interacting proteins, a combination of co-immunoprecipitation
assay (Co-IP) with mass spectrometry (MS) analysis will be conducted in the future.
Pak2 knock down Mino and Z138 stably expressing an N-terminal HA-tagged
full-length human Pak2 cDNA (HA-Pak2) will be generate using a retroviral system. The
following Pak2 immunoprecipitation (IP) analysis will be performed using anti-HA affinity
matrix. To map out the molecular interaction of Pak2, anti-HA Co-IP products will be examined by MS analysis. This approach will prove that the direct interaction between
Pak2 and specific proteins and give clues about the other potential binding interfaces.
Study of combination effects of PAKs inhibitor and BTK inhibitor in animal models
Our in vitro study had demonstrated that synergistic effect was existed between
FRAX 597 and ibrutinib or Adriamycin in lymphoma cell lines. FRAX 597 could also
overcome the ibrutinib resistant in MCL and ABC-DLBCL resistant cell lines. All these in
vitro data indicated the potential use of FRAX 597 as drug combination agent. Therefore,
in vivo study is needed to be done to further confirm the in vitro study.
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Cell line-derived xenograft and patient-derived xenograft mice models will be
used in the future study. Mice will be randomly divided into 4 groups and treated with
vehicle, ibrutinib 25 mg/Kg oral gavage daily alone, FRAX 597 25 mg/Kg intraperitoneal
injection daily alone and ibrutinib + FRAX 597 (ibrutinib 25 mg/kg oral gavage daily with
FRAX 597 25 mg/Kg intraperitoneal injection daily). Tumor volumes will be examined.
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Chapter 5 Materials and methods
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Cell lines and culture medium
MCL cell lines (Jeko-1, JVM2, Mino, Maver-1 and Z138 cells), ABC-DLBCL cell
lines (TMD8 and Ly3 cells), GCB-DLBCL cell lines (LY19 and DHL16 cells) and BL cell
lines (GA10 and Daudi cells) were cultured in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS; Invitrogen). Granta-519 cells and GP2-293T cells were cultured in
DMEM culture medium with 10% FBS. Naïve B cells were isolated from peripheral blood
mononuclear cells using a naïve B cell isolation kit (Miltenyl Biotec, CA). Normal B cells
were isolated from normal tonsil using a CD19 isolation kit (Miltenyl Biotec, CA).
Chemical reagents
Rac1 inhibitor NSC 23766 was purchased from Tocris Biosciences (Ellisville,
MO). PAK inhibitor FRAX 597 was purchased from Tocris Biosciences (Ellisville, MO).
BTK inhibitor ibrutinib was purchased from Selleckchem (Houston, TX).
Immunohistochemistry
Tissue from 32 MCL cases and 2 Tonsils were obtained from the University of
Nebraska Medical Center (UNMC), embedded in paraffin and arranged into tissue microarrays (TMAs). TMAs were deparaffinized in xylene followed by rehydration through
graded ethanol. Endogenous peroxidase was blocked using peroxidase-quenching solution (SuperPicture 3rd Gen IHC Detection Kit, Life Technology) for 10 min. The slides
were then boiled in citrate buffer (pH 6.0, Dako) for 1 hour, allowed to cool and rinsed
with PBS. The sections were incubated overnight at 4 °C with primary antibody (Rac1
1:100, #23A8 from EMD MILLIPORE) in Signal Stain antibody diluent (Cell Signaling
Technology). Slides were then washed with PBS and incubated with HRP polymer conjugate (SuperPicture 3rd Gen IHC Detection Kit) for 1 h at room temperature, followed by
PBS wash and then stained with DAB reagent. Photographs were taken using Roche
Ventana Scan HT. All clinical samples and features of the patients were retrieved from

130
the clinical database of Department of Pathology and Microbiology at UNMC. This study
was approved by the institutional review board of UNMC.
Gene expression profiling (GEP)
Previously, the LLMPP conducted a comprehensive GEP of MCL specimens. As
a result, a set of proliferation genes (proliferation signature) were identified representing
a biological integrator of oncogenic events associated with cell proliferation, which allowed the definition of prognostic subgroups that differ in median survival by more than 5
years102,103. In our study, GEP of 41 molecularly defined MCL cases from the LLMPP
were analyzed for Rac1 expression. Moreover, patients were divided into three groups
according to their Rac1 mRNA expression levels (high, median and low Rac1 groups,
see Table 1), then gene expression-based proliferation signatures between Rac1 high
and low groups was analyzed.
Antibodies and immunoblotting
Cell lysates were separated and immunoblotted by using Bolt® Bis-Tris system
(Life technology, Carlsbad, CA). Imaging and quantitative analyses were performed by
Odyssey CLX system (LI-COR Biosciences, Lincoln, NE). The antibodies for immunoblots are as follows: AKT (#4685), p-AKT (#4060), p-AKT (#13038), p-RPS6 (#4858),
RPS6 (#2217), 4E-BP1 (#9644), p-4E-BP1 (#2855), p-ERK1/2 (#4370), ERK1/2 (#4695),
p-P65 (#3033), P65 (#8242), cleaved-caspase (#9664) and PAK1/2/3 antibody sampler
kit (#4750) were all from Cell Signaling Technology (Danvers, MA). β-Actin (#SC-47778)
was from Santa Cruz Biotechnology (Dallas, TX). Rac1 (#23A8) was from EMD MILLIPORE (Billerica, Massachusetts). Anti-Pak1 (phospho S144) + Pak2 (phospho S141) +
Pak3 (phospho S154) antibody (ab4040795) was from Abcam (Cambriage, MA).
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Quantitative reverse transcription PCR (qRT-PCR)
RNA was isolated using The Quick-RNATM MiniPrep (Plus) kit (ZYMO Research).
The SuperScript®III First-Strand Synthesis System (Invitrogen) was used for cDNA synthesis. Real-time PCR was performed using DyNAmo HS SYBR Green qPCR kit (Thermo Scientific Inc.) with CFX connect (Bio-Rad, Hercules, CA) real-time thermocycler.
The ∆CT method was used to calculate the relative mRNA expression level by normalizing with the expression of housekeeping gene RPL13A. QRT-PCR primers used in this
study are as follows: Rac1 forward: CTGATGCAGGCCATCAAGT; Rac1 reverse:
TCTCCAGGAAATGCATTGGT. RPL13A forward: AGATGGCGGAGGTGCAG; RPL13A
reverse: GGCCCAGCAGTACCTGTTTA.

.

Rac1 activity assay
A glutathione-S-transferase (GST)-PAK1 (PAK-CRIB domain) fusion protein,
containing the Rac1 binding region from human PAK1B, was used to determine Rac1
activity as described104. Mino cells were pretreated with serum starvation (1% FBS containing medium) for 24h, followed by treated with different concentrations of NSC 23766
for 2 hours. This was then followed by adding epidermal growth factor (EGF) (SigmaAldrich) at 100 ng/mL for 15 min, re-suspension in lysis buffer (50 mM Tris-HCL (pH 7.4),
100 mM NaCL, 2 mM MgCL2 and 1 mM benzamidine; 1% NP-40; 10% glycerol; 1 µg/mL
leupeptin, pepstatin, and aprotinin) and centrifugation at 1500 rpm for 5 min at 4oC. For
negative control, supernatant protein was pretreated with 10mM EDTA (Boston BioProducts, Inc., Ashland, MA) and 1 mM GDP (20-177, EMD Millipore) for 15 min at
30oC with rotation. Equal amounts of supernatant protein (including negative control tube)
were incubated with the GST-PAK1 fusion protein bound to glutathione-coupled Sepharose beads at 4oC for 1h with rotation to capture GTP-bound Rac1. Beads were
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washed 3 times with lysis buffer and eluted in Laemmli buffer (60 mM Tris (pH 6.80), 2%
sodium dodecyl sulfate, 10% glycerin, 0.1% bromophenol blue). SDS-PAGE was performed on samples using a 4-20% gel and bound Rac1 analyzed by immunoblotting.
Rac1 shRNA knockdown in MCL cell lines
For the inducible shRNA expression, miR-E based shRNA105 was cloned into retroviral vector p-Retro-x (Clontech, CA). Virus was packaged by co-transfecting GP2293T cells with constructed vectors and pCL-ampho. After 48h of transfection, viruscontaining medium was collected and precipitated with PEG at 4°C overnight. Targeted
cells were then transduced with concentrated lentivirus with TransDux (System Biosciences, CA) and incubated for 48h followed by selection with puromycin. shRNA expression was initiated by Dox at 1 µg/mL and the knockdown efficiency was determined by
Western blot after 24h of induction. In all, two shRNAs were tested and the one with the
highest knockdown efficiency was chosen for subsequent functional studies. The Rac1shRNA sequences are shRNA1: gggcatttaattcatcttta, and shRNA2: cgacactgtcacttgaccaa.
Rac1 overexpression in MCL cell lines
For transduction, pcDNA3-EGFP-Rac1-wt was modified into a retroviral expression plasmid pMIP-w containing WRE element and puromycin resistant gene as selection marker, which as modified from pMIG-w, a gift from Luk Parijs (Addgene plasmid
#12282). Expression plasmid was mixed with pCL-Ampho retrovirus packaging vector
(Novus) in the presence of TransIT-LT1 transfection reagent, and then were transfected
into GP2-293T cells. Virus containing culture medium was collected from GP2-293T at
48h and 72h post transfection. Virus was concentrated using PEG-it Virus Precipitation
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Solution (System Biosciences) and resuspended with RPMI medium and Transdux (System Biosciences) to infect MCL cell lines (JVM2 and Z138 cells).
Rac1, Pak1 and Pak2 silencing
To inhibit expression of Rac1, Pak1 or Pak2 gene, a pool of specific siRNAs was
purchased from IDT and transfected using NEON Transfection System (Invitrogen,
Carlsbad, CA). In detail, 4*105 were transfected with a 10 μl‐tip at 40nM concentration of
siRNA pool, or with mock transfection buffer alone. After electroporation, cells were
seeded into cell culture six‐well plates and incubated for 48 h before additional treatments.
Analysis of viability and apoptosis
Cell proliferation and viability were determined by Presto Blue cell proliferation/viability assay kit (Invitrogen, CA) following the manufacturer’s instructions. Fluorescence intensity was measured using Plate reader Infinite® 200PRO (Tecan, Switzerland)
at 560 nm for excitation and 590 nm for emissions. Apoptosis was determined by Annexin V-FITC and propidium iodide (PI), or Annexin V-PE and 7-AAD staining (BD
Pharmingen) according to the manufacturer’s instructions followed by quantification using a FACS Calibur flow cytometer (BD Biosciences).
Statistical analyses
For correlation and survival analyses, patients were divided into two groups according to Rac1 IHC staining (cutoff: 30%). Pearson’s w2-test was used to analyze correlations between Rac1 status and OS or event free survival (EFS). Survival was estimated using the Kaplan–Meier method, and the comparison between study groups was
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performed with the log-rank test. The end-point EFS was calculated as time from diagnosis to the first documented recurrence.
For in vitro experiments, group comparisons were evaluated using the two-tailed,
unpaired t-test (equal variance). All statistical analyses were performed using SPSS 16.0
and are shown as means ± SD (standard deviation). P-values <0.05 was considered
significant.
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